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Abstract
The gene PTPN11 was identified in the early 1990s, and encodes the nontransmembrane protein tyrosine phosphatase SHP2. SHP2 is expressed ubiquitously in
cells, and plays an important role in cancer. Unlike most phosphatases, SHP2 positively
regulates several signaling pathways including the Ras/MAPK and Src signaling
pathways and acts as a proto-oncogene. SHP2 is also a cancer essential gene in
certain types of carcinomas, and promotes growth, survival, and epithelial to
mesenchymal transformation. Gain of function (GOF) SHP2 mutations are known
leukemic oncogenes, and have been identified to a smaller extent in solid tumors as
well. Currently, the roles of SHP2 in lung carcinoma are not fully understood. While
GOF SHP2 mutations have been detected in lung cancer, their contributions to cellular
transformation had not been established. In addition, SHP2 is known to promote EGF
growth factor receptor (EGFR) signaling. Since GOF EGFR mutations induce
transformation of lung epithelial cells, it is possible that SHP2 plays a role in promoting
GOF EGFR mutant driven tumorigenesis. The objective of this dissertation is to
determine whether SHP2 can act as an oncogene in lung epithelial cells and whether
SHP2 inhibition can affect GOF EGFR mutant induced lung cancer. To achieve these
aims, we generated two novel doxycycline (Dox) inducible transgenic mouse models
which express either the GOF SHP2E76K leukemic oncogene or the dominant negative
SHP2CSDA mutant under the control of the Clara cell secretory protein (CCSP) promoter
to regulate transgene expression to type II pneumocytes.
ix

To determine whether SHP2 plays a role in promoting GOF EGFR mutant signaling,
we started by disrupting SHP2 function in vitro. Two non small lung cancer cell lines
were used for this project: HCC827 carries the LREA deletion in exon 19, and H1975
co-expresses the EGFRL858R point mutation and the EGFRT790M gatekeeper mutation.
After SHP2 PTP inhibition or knock-down by shRNA and siRNA, both cell lines exhibited
decreased cell proliferation and reduced levels of pErk1/2 and c-Myc. Based on these
results, we acquired a transgenic mouse line which expresses the EGFRL858R mutant
under the control of the tet-O promoter and generated bitransgenic CCSP-rtTA/tetOEGFRL858R and tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice to study
the effects of the dominant negative SHP2CDSA mutant on EGFRL858R mediated
carcinogenesis in vivo. After 4, 6, and 8 weeks of Dox induction, pErk1/2 and pSrc
levels were increased in the lungs of bitransgenic mice compared to wild type controls.
Both kinases were suppressed by SHP2CSDA expression in tritransgenic mice. In
addition, SHP2CSDA expression delayed tumor onset and prevented progression to a
more aggressive phenotype. Tritransgenic mice also developed a smaller tumor burden
compared to bitransgenic animals. These results suggest that SHP2 is critical for GOF
EGFR mutant mediated lung tumorigenesis and describe a new role of SHP2 as a
potential therapeutic target for the development of novel NSCLC drugs.
Once we generated our CCSP-rtTA/tetO-SHP2E76K transgenic mouse model, we
administered Dox for one month and found that SHP2E76K expression upregulates
pErk1/2, pSrc, pGab1, c-Myc and Mdm2 levels in the lungs of bitransgenic mice
compared to controls. After six to nine months of Dox induction, SHP2E76K expression
caused formation of lung adenomas and adenocarcinoma. We then took advantage of
x

the reversible feature of our mouse model to test whether lung tumors are dependent on
sustained SHP2E76K expression for survival. MRI analysis of lung adenocarcinomas
showed full regression of the lung tumors after Dox withdrawal. Histological evaluation
of lung tissues revealed residual hyperplastic lesions as well as evidence of necrosis,
while biochemical analysis showed that pGab1, pErk1/2, pSrc and c-Myc returned to
basal levels. These results demonstrate that sustained SHP2E76K expression is required
for lung tumor maintenance. Moreover, this data describe a novel function of SHP2E76K
as an oncogene in lung carcinoma.

xi

Chapter 1: Introduction

1.1 Protein tyrosine phosphatases and protein tyrosine kinases
Tyrosine phosphorylation is an essential step to induce cell signaling and was first
reported in 1978 with the discovery of the Src tyrosine kinase [1, 2]. Extensive research
has identified a multitude of protein tyrosine kinases (PTKs) and elucidated their roles in
normal cellular function and cancer. Since for every action, there must be an equal and
opposite reaction, the concept of a protein tyrosine phosphatase (PTP) which
dephosphorylates tyrosine sites (Y) phosphorylated by PTKs was proposed. This
hypothesis was confirmed a decade after the discovery of PTKs with the cloning of the
protein tyrosine phosphatase PTP1B [3, 4]. Since then, the human “PTPome” has been
extensively characterized with the identification of 107 PTPs grouped into four families.
The majority of PTPs are included in the class I cysteine based group, and include the
classical receptor PTPs, the non receptor PTPs and the dual specificity PTPs [5]. Class
II includes the low molecular weight PTP and class III contains 3 Cdc25 proteins. Both
class II and III are cysteine based. The fourth class includes Asp based PTPs [5].
The common assumption at the time was that since PTPs perform the reverse
function of PTKs, they should play a negative regulatory role in cell signaling and
cancer. This idea was reinforced by the discovery and characterization of PTPs such as
PTEN, DEP1, and TCPTP which decrease or terminate cell signaling and block
activation of downstream targets of receptor tyrosine kinases (RTKs) [6-9]. Moreover,
1

these PTPs are often inactivated or lost through mutation, which potentiates cellular
transformation leading to cancer development [10, 11]. These studies cemented the role
of PTPs as negative regulators of cell signaling.
Further research revealed that tyrosine phosphorylation by RTK does not always
activate the target protein [12]. Indeed, multiple proteins are negatively regulated by
tyrosine phosphorylation, which would indicate that dephosphorylation by a PTP would
have a positive effect on cellular signaling [13-16]. This hypothesis was confirmed in
2003 with the identification of GOF SHP2 mutations in patients afflicted with juvenile
myelomonocytic leukemia [17]. In this disease, SHP2 acts as a proto-oncogene and
drives leukemogenesis [18, 19]. Following this discovery, additional PTPs were found to
act as proto-oncogenes, including RPTPα, PTPH1, and more [5, 20, 21]. These PTPs
promote cell signaling, cellular transformation, survival, proliferation, and invasion [5].
Taken together these studies describe complex and opposing roles for the members of
the PTPome in normal cellular function, development and cancer. PTPs are an
important component of signal transduction, and should not be solely considered
erasers of PTKs function.

1.2 Discovery of the protein tyrosine phosphatase SHP2
The gene PTPN11 was discovered in the early 1990s, and encodes the nontransmembrane protein tyrosine phosphatase Src homology 2 domain tyrosine
phosphatase (SHP2), previously called Syp, PTP1D, SH-PTP2, or PTP2C [22-25].
SHP2 contains a C-terminal tail with two tyrosyl phosphorylation sites (Y542 and Y580),
a central PTP catalytic domain, and two N-terminal Src homology 2 (SH2) binding
2

domains (N-SH2 and C-SH2) (Fig. 1). SHP2 is regulated by an auto-inhibitory
mechanism. In its inactive conformation, the N-SH2 binding domain folds over the PTP
domain and restricts substrate access to the catalytic site (Fig. 1). Upon growth factor or
cytokine stimulation, the SH2 binding domains bind to phosphorylated tyrosine sites on
growth factor receptors or docking proteins causing SHP2 to unfold, exposing the PTP
catalytic domain [26]. SHP2 is expressed ubiquitously, and plays an important role in
development, normal cellular function, and cancer [27, 28]. Unlike most phosphatases,
SHP2 positively regulates cell signaling and acts as a proto-oncogene [29].

Figure 1. Crystal structure of SHP2. The crystal structure of un-liganded SHP2 was
resolved in 1998 by the Shoelson group [30]. This structure is missing the c-terminal tail
but otherwise contains the C-SH2 binding domain (yellow), the N-SH2 binding domain
(red) and the PTP catalytic domain (green). The structure is in its inactive conformation,
whereas the N-SH2 binding domain folds over the PTP domain and blocks substrate
access to the catalytic cleft (magenta).
3

1.3 SHP2 is a positive regulator of cell signaling
SHP2 is activated by several growth factor receptors including the platelet derived
growth factor receptor (PDGFR), the epidermal growth factor receptor (EGFR), the
fibroblast growth factor receptor (FGFR), and the insulin-like growth factor 1 receptor
(IGF-1R) [31, 32]. As a result, SHP2 is involved in multiple cell signaling pathways and
performs different roles depending on the activating growth factor receptor, though the
main function of SHP2 is to promote the Ras/MAPK and Src signaling pathways through
multiple incompletely defined mechanisms.

1.3.1 The role of SHP2 in the Ras/MAPK signaling pathway
An important mechanism for the promotion of Ras/MAPK signaling by SHP2 is its
association with the docking protein Grb2 associated binder protein 1 (Gab1) [33, 34].
Phosphorylation of Gab1 on its SHP2 binding sites (Y627, Y659) by growth factor
receptors recruits SHP2 to the cell membrane and relieves the auto-inhibitory
mechanism, exposing the PTP catalytic domain (Fig. 2) [35]. Once activated, SHP2
positively regulates Ras/MAPK signaling through both direct and indirect approaches.
For example, PDGFR binds SHP2 which in turn directly recruits the growth factor
receptor bound protein 2 (Grb2)/Son of Sevenless (SOS) complex to the cell membrane
(Fig. 2) [31, 36]. SOS is a guanine nucleotide exchange factor that catalyzes the
conversion of inactive GDP-bound Ras to active GTP-bound Ras, leading to activation
of the Ras/MAPK signaling chain [37].

4

SHP2 can also indirectly prolong Ras/MAPK activity by interfering with the negative
regulators of this signaling pathway such as p120RasGAP and the Sprouty-related,
EVH1 domain-containing protein (SPRED) and Sprouty protein families. The
p120RasGAP protein catalyzes hydrolyzation of the GTP-bound Ras to the inactive
GDP-bound state [38]. To perform this function, p120RasGAP must bind to specific
tyrosine sites on growth factor receptors or scaffolding protein such as Gab1. SHP2
dephosphorylates these sites, which disrupts p120RasGAP function by blocking its
recruitment to the cell membrane (Fig. 2) [36]. Sprouty is another negative regulator of
Ras. This protein functions by binding Grb2 and sequestering the Grb2/SOS complex in
the cytoplasm to prevent SOS mediated Ras activation [39]. SHP2 dephosphorylates
the Grb2 binding site on Sprouty, enabling relocation of the Grb2/SOS complex to the
cell membrane (Fig. 2). Finally, the SPRED family of proteins contains a Sprouty related
domain that can bind Ras. The SPRED/Ras complex recruits Raf to the cell membrane,
whereas Raf activation through phosphorylation of its Serine338 site is blocked by
SPRED. This results in termination of Ras/MAPK signaling [40]. SPRED is a substrate
of SHP2 which dephosphorylates the SPRED activating tyrosine sites to restore
Ras/MAPK signaling pathway activity (Fig. 2) [41].

1.3.2 The role of SHP2 in the Src family kinase signaling pathway
SHP2 interaction with the members of the Src family of kinases (SFKs) is complex
and sometimes tissue specific. For example, after recruitment by the α6β4 integrin,
SHP2 binds Fyn and dephosphorylates its negative regulatory tyrosine site. Active Fyn
promotes integrin signaling leading to cell growth, migration, and survival [42]. In
5

hematopoietic cells, the Grb2 associated binder protein 2 (Gab2) recruits both SHP2
and Lyn after G-CSF stimulation. SHP2 then activates Lyn, which in turn induces cell
proliferation [43]. Once the SFKs are activated, they can initiate a negative feedback
loop by phosphorylating the CSK binding protein (Cbp) SH2 binding sites. Cbp then
binds the Src kinase and recruits the C-Src tyrosine kinase (CSK). CSK is a negative
regulator of the SFKs, and normally resides in the cytoplasm [44]. Cbp complex
formation with SFKs and CSK results in phosphorylation of the SFKs c-terminal
inhibitory tyrosine site by CSK, thus terminating Src signaling [44]. SHP2 can interfere
with this negative regulatory mechanism by dephosphorylating Cbp to block relocation
of CSK to the cell membrane (Fig. 3) [45].

Figure 2. Function of SHP2 in Ras/MAPK kinase signaling pathway. SHP2 is recruited
to the cell membrane by an active RTK and binds the Grb2/SOS complex to initiate
Ras/MAPK signaling. SHP2 also dephosphorylates the Sprouty, SPRED, and
p120RasGAP binding sites to prevent their recruitment to the cell membrane and
termination of Ras/MAPK signaling.

6

Figure 3. Function of SHP2 in Src kinase signaling pathway. SHP2 dephosphorylates
the CSK binding site on both Paxillin and Cbp, leading to Src activation.

1.3.3 The role of SHP2 in the PI3K and Jak/STAT1 signaling pathway
SHP2 functions differently in the Phosphatidylinositol-4, 5-bisphosphate 3-kinase
(PI3K) signaling pathway depending on the activating growth factor and tissue type.
After stimulation with IGF, PDGF, or Thrombopoietin, SHP2 associates with the PI3K
subunit p85 and induces Akt activation in mouse fibroblasts, glioblastoma cells and
megakaryocytes, promoting cell proliferation and survival [46-48]. On the other hand,
EGF stimulation causes the opposite effect. In this case, SHP2 dephosphorylates the
p85 binding sites on Gab1, leading to decreased p85/SHP2/Gab1 association and Akt
phosphorylation [49, 50]. These opposing effects on PI3K signaling further add to the
complexity of SHP2 function in signal transduction.
The Janus kinase (Jak)/Signal Transducers and Activators of Transcription 1
(STAT1) signaling pathway activation by type I and II interferons (IFN) elicits a strong
anti-proliferative response which is negatively regulated by SHP2 [51]. Indeed, SHP2
7

dephosphorylates STAT1 after Jak1/2 phosphorylation, disrupting the formation of
STAT1 dimers and translocation to the nucleus [52]. This inhibitory mechanism is
particularly deleterious in post surgery melanoma patients treated with IFNα adjuvant
therapy. Previous work in our lab has shown that SHP2 can restore Ras/MAPK
signaling pathway activity post IFN-α2b treatment which significantly curtails the antiproliferative effects of IFNα therapy [53]. In addition, SHP2 can also regulate STAT1 in
a phosphatase independent manner by binding and sequestering non-phosphorylated
STAT1 in the cytoplasm [54].

1.4 SHP2 and cancer
SHP2 is a cancer essential gene in certain types of carcinomas. For example, SHP2
is required for survival of tumor initiating cells, tumor growth, and metastasis in Her2
positive and triple negative breast cancers [55, 56]. SHP2 is also required to potentiate
EGFRvIII mediated cellular transformation in glioblastoma and SHP2 knock-down in
these cells hinders cell-cycle progression and EGFRvIII mediated cell signaling [57].
Moreover, SHP2 is a proto-oncogene. Activating SHP2 mutations in the N-SH2 binding
domain or the PTP domain disrupt the auto-inhibitory mechanism, conferring
constitutive activity to the PTP catalytic domain (Fig. 4). These GOF SHP2 mutants can
induce myeloproliferative disorders and act as leukemic oncogenes. They have been
identified in 35% of juvenile myelomonocytic leukemia, 10% of childhood
myelodysplastic syndromes, 7% of B-cell acute lymphoblastic leukemia, 4% of acute
myelogenous leukemia, and a small percentage of carcinomas [58, 59].
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Figure 4. GOF SHP2 mutations. The majority of the GOF function SHP2 mutations are
located in the N-SH2 or PTP binding domain and disrupt the auto-inhibitory mechanism,
conferring constitutive activity to the PTP catalytic domain.

Since SHP2 is involved in multiple signaling pathways, the acquisition of an
activating mutation results in a myriad of phenotypic changes. Indeed, GOF SHP2
mutations partly induce cellular transformation by upregulating the Ras/MAPK and Src
signaling pathway, leading to increased cell proliferation and survival [60, 61]. In
myeloid progenitor cells, GOF SHP2 mutants promote cytokine independent survival
while causing hypersensitivity to GM-CSF and IL-3 [62]. Activating SHP2 mutants also
induce centrosome amplification which disrupts cell division and causes genomic
instability [63]. In addition, mutated SHP2 causes an expansion of the myeloid
progenitor cell compartment by blocking the differentiation of early stage hematopoietic
progenitors. This process also causes anemia by disrupting normal erythropoiesis [64].
Activating SHP2 mutations have been identified at low frequencies in several cancer
types such as lung (1.81%), colon (5.98%), and endometrium (4.27%) according to the
9

COSMIC database as of April 2014, but might play an important role nevertheless. For
example, in a study performed by Sturla et al, GOF SHP2 mutations were identified in
2% of glioblastoma patient samples, and protected tumor cells against senescence [65].
The potential role of SHP2 as an oncogene in carcinoma is still unknown, and further
study is required to understand the contributions of GOF SHP2 mutations to epithelial
tumorigenesis.

1.5 Lung cancer
Lung cancer is the most prevalent type of cancer in the United States. According to
the American cancer society, there will be about 224,210 new cases in 2014, leading to
approximately 159,260 deaths (about 27% of all cancer deaths). Lung cancer is divided
in two classes, small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).
About 80% of cases fall under the NSCLC category, which is further subdivided in three
groups: squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [66].
Each group presents unique histological features and arises in different areas of the
lung. Adenocarcinoma is the most commonly indentified subtype in patients. Multiple
driver oncogenes have been identified in adenocarcinoma (Fig. 5), and have been
targeted for drug development [67]. Unfortunately, the majority of patients develops
drug resistance and relapses [68-71]. Moreover, in about 40% of cases the transforming
factor is unknown, highlighting an urgent need for alternative therapies. The
identification and targeting of the cell of origin of lung cancer could provide a new
avenue for therapeutic treatment.
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Figure 5. Common driver oncogenes in adenocarcinoma. Adenocarcinoma is a subtype
of non small cell lung cancer. Several driver oncogenes have been identified and
provide valuable targets for drug development.

The concept of a lung cancer cell of origin has generated a lot of interest, and
multiple research teams have tried to identify this cell population. Previous studies using
lung tissue have established a novel cell type located at the bronchioloalveolar ductal
junction with positive expression of both the Clara cell antigen 10 (CC10) and the
alveolar type II marker Surfactant protein C (SPC) [72, 73]. These cells are called
bronchioloalveolar stem cells (BASCs), and while normally quiescent, become activated
following injury and give rise to type I and II pneumocytes. Further work using mouse
models supported that BASCs are the cell type from which adenocarcinomas could
arise [72, 73]. In squamous cell carcinoma, progenitor tracheal basal cells are the
tentative candidate for cell of origin due to similar patterns of gene expression and
histological features, but further work is required to confirm this hypothesis [72].
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The SCLC cell of origin has been difficult to identify due to tumors often exhibiting
mixed cell types and cell surface markers. In general, SCLC is thought to arise from
neuroendocrine progenitor cells based on shared patterns of neuroendocrine markers
and gene expression [72, 74]. This hypothesis was supported by data from the Kim lab
using a mouse model where deletion of the p53 and Rb genes in neuroendocrine cells
located in the lung epithelium resulted in hyperproliferative lesions [74].
Aside from BASCs and neuroendocrine progenitor cells, cancer stem cells have also
been proposed as the cell of origin for lung cancer. Previous studies have identified a
novel lung cell type termed side population (SP) which displays characteristics similar to
stem cells described in other tumor types [75]. Lung SP cells efflux Hoechst 33342 dye
and express stem cell markers such as CD133, ALDH, and CD 44 [75, 76]. Lung SP
cells are usually in a quiescent state, are resistant to chemotherapy, and express genes
involved in self-renewal such as Sox2, Nanog, and Oct 4 [77]. Interestingly, this side
population is enriched with tumor initiating cells and demonstrates self renewal, tumor
repopulating capacity, and have been identified in lung patient tumor samples [78, 79].
Based on this evidence, a strong case can be made that lung cancer is initiated by the
deregulation and uncontrolled division of lung cancer stem cells and that lung SP cells
could provide a valid therapeutic target for lung cancer treatment [75].
The identification of the lung cancer cell of origin can provide valuable insight into
lung tumorigenesis and could open up new avenues for drug development. Extensive
research has been done to characterize these cells, but at this stage further study is
required to better understand and fully determine their roles in lung carcinogenesis in
order to target them for therapeutic treatment.
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1.6 The epidermal growth factor receptor
The EGF receptor is a member of the ErbB tyrosine kinase family, and is composed
of a cytoplasmic protein tyrosine kinase domain, a single membrane spanning region,
and an extracellular ligand binding domain (Fig. 6). Upon ligand binding by a member of
the EGF family of ligands, the EGF receptor homo or hetero-dimerizes with a member
of the ErbB family resulting in intrinsic kinase trans-activation [80]. The autophosphorylation of the EGFR c-terminal tyrosine docking sites recruits a variety of
adapter proteins, kinases, and phosphatases, which induce the activation of several
signaling pathways involved in cell growth, differentiation, survival and more [81].

1.6.1 EGFR activation induces cell signaling

1.6.1.1 EGFR and the Ras/MAPK signaling pathway
EGFR activation upon ligand binding and dimerization induces the Ras/MAPK cell
signaling pathway by recruiting the Grb2/SOS complex to the cell membrane [82]. SOS
is a guanine nucleotide exchange factor that catalyzes the conversion of inactive GDPbound Ras to active GTP-bound Ras. Ras binds multiple targets, but its main function is
to activate Raf by inducing a conformational change that disrupts Raf association with
the inhibitory protein 14-3-3. This triggers activation of the Raf/Mek/MAPK signaling
chain, leading to MAPK translocation to the nucleus and activation of transcription
factors that promote cellular growth, proliferation, differentiation and survival [83-85].
13

1.6.1.2 EGFR and the Src family kinase pathway
Previous studies have described several mechanisms of EGFR mediated SFK
signaling pathway activation [86]. EGF ligand binding induces translocation of the
Src/SHC complex to the cell membrane whereas SHC binds active EGFR, leading to
Src activation [87]. SHC is an adapter protein which associates with multiple partners
upon phosphorylation by RTKs [88]. EGF stimulation can also recruit SHP2 to the cell
membrane, where it binds to protein complexes composed of Gab1, Paxillin, CSK, or
Src. SHP2 dephosphorylates the CSK binding sites on Paxillin, leading to Src activation
(Fig. 3) [34]. Src activation by EGFR also triggers a positive feedback loop whereas
active Src can in turn phosphorylate and promote EGFR activity, resulting in increased
cell proliferation, migration, and anchorage-independent growth [86, 89].

1.6.2 EGFR and cancer
EGFR over expression or amplification in several types of cancer including breast,
glioblastoma, and gastrointestinal carcinoma is a negative prognosis marker of survival
in patients [90-92]. Moreover, GOF EGFR mutations are oncogenic and induce cellular
transformation. They have been identified predominantly in lung cancer, but are present
in additional cancer types including malignancies of the central nervous system
(4.77%), prostate (3.94%), intestine (4.46%), and more according to the COSMIC
database as of April 2014.
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Lung cancer is divided in two histological subtypes, non-small cell lung cancer and
small cell lung cancer. Non small cell lung cancers make up about 80% of cases, and
are further sub-divided into three groups, squamous cell carcinoma, large cell
carcinoma, and adenocarcinoma [93]. GOF EGFR mutations are present in about
27.54% of lung adenocarcinoma cases according to the COSMIC database.
Interestingly, patients with GOF EGFR mutations are usually never smokers or females
of Asian descent. The mechanisms underlying this apparent sensitivity have not been
fully elucidated [94-96].

1.6.2.1 Gain of function EGFR mutations
GOF EGFR mutations are classified in two main groups: extracellular domain
mutations or tyrosine kinase mutations. The prevalence of these two classes of
mutations differs based on cancer type.
Extracellular domain mutations.
Previous studies have identified three types of EGFR mutations with extracellular
domain deletion. They are classified based on the extent of the extracellular domain
deletion. The first type, called EGFRvI, exhibits a complete deletion of the extracellular
domain while the second type, EGFRvII, contains an 83 amino acid deletion in domain
IV [97]. This mutation does not appear to contribute to tumorigenesis [97]. The third and
most commonly identified type, EGFRvIII, lacks domain I and II of the extracellular
ligand binding domain (Fig. 6), and is often amplified. This mutation confers constitutive
kinase activity and is common in glioblastoma (30-50% of cases) and has been reported
in about 5% of squamous cell carcinoma patients [98-100].
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Tyrosine kinase domain mutations
About 90% of tyrosine kinase domain mutations are sub-divided in two groups. The
first group contains a small deletion, usually amino acids 746-750, in exon 19. The
second group contains a missense mutation on exon 21 substituting leucine for arginine
at codon 858 [97]. Multiple variants of these two mutations have been described, and
include larger deletions, point mutations and insertions, notably in exon 20 (Fig. 6)
[101]. Interestingly, tyrosine kinase domain mutations are usually identified in lung
cancer, and tend to be mutually exclusive with other oncogenes such as KRAS [97].

Figure 6. Common GOF EGFR mutations in glioblastoma and lung cancer. Extracellular
domain mutations are often identified in glioblastoma and exhibit partial to entire
deletion of the extracellular domain. Kinase domain mutations are usually identified in
lung cancer, and can be found in multiple exons of the tyrosine kinase domain.

1.6.2.2 EGFR as a therapeutic target in NSCLC
The establishment of GOF EGFR mutations as a valid therapeutic target in NSCLC
led to the development of multiple specific tyrosine kinase inhibitors (TKIs). Gefitinib
(Iressa) was the first of its kind and showed promising anti-tumor potential in vitro and in
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vivo. This small molecule inhibitor blocks receptor autophosphorylation by competing
with ATP for binding to the intracellular ATP binding pocket of mutant EGFR [102].
Gefitinib treatment abrogates GOF EGFR mutant signal transduction leading to
decreased cell growth, proliferation and survival [103]. These effects are mediated
through multiple mechanisms. For example, Gefitinib promotes G1 phase arrest through
upregulation of p27 and suppresses angiogenesis by decreasing VEGF levels [104,
105]. Gefitinib also decreases cell survival by upregulating BAD, a pro-apoptotic
member of the Bcl-2 family of apoptosis regulators [106].
Phase I clinical trials reported Gefitinib is well tolerated in patients, with most side
effects falling within Common Toxicity Criteria grade 1 or 2 [107]. Several phase II trials
proved the efficacy of Gefitinib in patients with NSCLC [107]. Of these trials, the Iressa
dose evaluation in advanced lung cancer 1 (IDEAL1) trial demonstrated a response rate
of 18.4% with a median progression free survival of 2.7 months and an overall survival
rate of 7.6 months, establishing Iressa as a valid therapeutic agent in the treatment of
advanced lung cancer [108]. Based on these results, two phase III clinical trials termed
Iressa NSCLC Trial Assessing Combination Treatment (INTACT) 1 and 2 were
undertaken to compare a combination of Cisplatin and Gemcitabine with Gefitinib or a
combination of Carboplatin and Paclitaxel with Gefitinib to chemotherapy alone.
Unfortunately, Gefitinib treatment did not improve overall survival in patients compared
to placebo controls [70, 71]. Despite these results, Iressa was approved as a third line
therapy after failure of Docetaxel and platinum based chemotherapies by the FDA on
May 3rd 2003 [109]. An important point is that these clinical trials were performed
without checking the mutation status of the EGF receptor [110]. Subsequent studies
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demonstrated that lung cancer patients carrying a GOF EGFR mutation have a
significantly higher response rate and time to disease progression compared to patients
with wild type EGFR [111, 112]. The Iressa pan-Asia study (IPASS) further validated
these results by describing a 71.2% objective response rate in patients carrying a GOF
EGFR mutation. Based on this data, Gefitinib is administered as a first line therapy to
East Asian lung cancer patients with GOF EGFR mutations [113]. The success of
Gefitinib paved the way for the development of a host of novel agents ranging from
small molecule tyrosine kinase inhibitors to monoclonal EGFR antibodies [114, 115].

1.6.2.3 Resistance and relapse to EGFR tyrosine kinase inhibitors
Despite the initial efficacy of EGFR tyrosine kinase inhibitors, several studies have
shown that the majority of patients stop responding to treatment and relapse. These
reports prompted a search to determine the mechanisms of acquired resistance to
EGFR tyrosine kinase inhibitors. Pao et al was one of the first groups to describe the
T790M mutation in patients resistant to Gefitinib treatment [116]. This mutation is
present concurrently with Gefitinib sensitive GOF EGFR mutations, and induces a
conformational change that interferes with Gefitinib binding and significantly increases
receptor affinity for ATP [117-119]. Acquisition of the T790M mutation occurs in about
50% of lung cancer patients treated with EGFR tyrosine kinase inhibitors and is the
main cause of TKIs drug resistance [120]. Additional mechanisms of resistance have
been described, including activation of alternative tyrosine kinases (IGF-1R and PI3K)
or c-Met amplifications [121-123]. While multiple approaches aiming to overcome these
mechanisms of resistance are currently being studied, there is an urgent need for the
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identification of novel therapeutic targets to develop treatments for patients who have
failed both chemotherapy and EGFR targeted therapy [67, 124].

1.7 Mouse models
Mouse models are an invaluable tool to study the effects of targeted gene alterations
on development and disease. Since the generation of the first genetically modified
animals in the early 70s, mouse models have become the de facto option to study gene
modification in vivo [125, 126]. There are currently multiple approaches available to
generate mouse models.

1.7.1 Techniques for mouse model generation
The knock-out system causes partial to total deletion of the gene of interest,
resulting in the expression of a non-functional truncated protein or no protein at all [127].
On the other hand, the knock-in system makes use of homologous recombination to
insert a mutated gene in its original locus, replacing the wild type gene in the process
[128]. These two approaches have many advantages. Targeted insertion/deletion of the
gene of interest in its original locus ensures gene expression is comparable to wild type
and also prevents disruption of critical genes, a common issue when using random DNA
integration. The main drawback with these approaches is that the gene modification is
irreversible, so dependency of the observed phenotype on sustained gene
expression/deletion cannot be determined. This issue was corrected with the
development of inducible transgenic mouse models [128]. One of the main approaches
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uses the Dox-inducible reverse tetracycline transcription regulation system. In the
presence of Dox, the reverse tetracycline transactivator (rtTA) binds the tet operon
promoter (tetO) and induces transcription of the transgene [129]. Transgene expression
can be restricted to the organ or cell type of interest by expressing rtTA under the
control of a tissue specific promoter [130-132]. Since we are interested in lung cancer,
we acquired a mouse strain developed by the Whitsett group, which uses the Clara cell
secretory promoter (CCSP) to restricts transgene expression to type II pneumocytes in
bitransgenic animals [131].

1.7.1.1 Cre recombinase mediated cassette exchange system
The generation of transgenic, knock-in or knock-out models is a time consuming and
costly process. Each new founder line needs to be fully characterized before use, and
the random integration and expression levels of DNA in transgenic mouse models
makes comparison of transgene expression between two different mouse models
unreliable. To address these issues, the Wahl group designed the Cre-recombinase
mediated cassette exchange system (RMCE) [133]. They started by designing a novel
LoxP site that differs from the original LoxP site by three nucleotides to avoid
recombination between the two sites. They then generated a cassette where the
hygromycin phosphotransferase-thymidine kinase (HyTK) was flanked by the original
and novel LoxP sites (termed L2 and L3). The cassette was inserted in the DHFR locus
by homologous recombination or at random sites in the genome through single copy
integration using a retrovirus [133]. After confirming the presence and expression of the
transgene, RMCE was performed using a donor LoxP target. RMCE efficiently induced
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site specific recombination and incoming transgene showed expression levels
comparable to original transgene (Fig. 7) [133]. These results establish RMCE as an
excellent tool to quickly and efficiently generate novel transgenic mouse models with
comparable gene expression.

Figure 7. Cre recombinase mediated cassette exchange system. The gene is flanked by
oppositely oriented hetero-specific LoxP sites and inserted in the genome. In the
presence of Cre recombinase, the corresponding LoxP sites from the original cassette
recombine with the LoxP site on the replacement cassette replacing the original gene
with the DNA from the donor plasmid.

1.7.2 SHP2 mouse models
To determine the role of SHP2 in normal cellular development and cancer, multiple
mouse models have been generated. One of the first models used a knock-out
approach to delete part of the N-SH2 binding domain (SHP2∆46-110). Homozygous
SHP2∆46-110 embryos did not survive past E11.5. At an earlier time point, homozygous
SHP2∆46-110 embryos were present but displayed severe developmental abnormalities
and growth retardation compared to wild type littermates [134]. Further study revealed
that the morphological abnormalities seen in SHP2∆46-110 embryos were most likely
caused by the impaired ability of the mutant SHP2 to activate the Ras/MAPK pathway
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downstream of activated PDGFR and FGF [134]. To determine the effect of pan-SHP2
knock-out in adult mice, Bauler et al developed a tamoxifen inducible estrogen receptor2 cre transgenic mouse model with homozygous floxed ptpn11 (ptpn11fl/fl ert2-cre)
[135]. Adult mice displayed impaired hematopoiesis and osteoclastogenesis, cartilage
abnormalities, as well as pronounced kyphosis and scoliosis [135]. Targeted SHP2
knock-out in type II alveolar epithelial cells using the SPC-rtTA/tetO-Cre/SHP2fl/fl mouse
model caused spontaneous interstitial fibrosis induced by impaired surfactant protein
metabolism [136]. These mouse modeling studies established SHP2 as an essential
player in embryonic development and survival. Moreover, SHP2 also plays a key role in
adult animals, and is required for proper bone and lung epithelial cell homeostasis as
well as hematopoiesis.
Aside from its role in development and normal cellular function, SHP2 is also an
important factor in cancer. Since SHP2 is a known leukemic oncogene, multiple mouse
models were developed to study the role of SHP2 in leukemogenesis [17, 137]. The Qu
and Neel groups both generated a knock-in GOF SHP2 mutant mouse model
(Ptpn11D61G/+) to determine the mechanism of leukemogenesis and study Noonan
syndrome in vivo. Several Ptpn11D61G/+ organs displayed elevated pErk1/2 and pAkt
levels and hematopoietic stem cells (HSCs) showed hypersensitivity to GM-CSF and IL3 [61, 138]. Ptpn11D61G/+ mice also showed activation of quiescent HSCs, development
of myeloproliferative disease (MPD) and splenomegaly [61]. Interestingly, Ptpn11D61G
mediated MPD was dependent on the presence of Gab2 [61]. A knock-in mouse model
using the GOF Ptpn11E76K mutant (Ptpn11E76Kneo/+/Mx1-Cre+) exhibited a similar
phenotype to Ptpn11D61G/+ mice with the development of MPD. In addition, these mice
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progressed to leukemia and displayed severe impairment of hematopoietic
differentiation and GM-CSF/IL-3 hypersensitivity [63]. These mouse modeling studies
determined that SHP2 co-localizes with centrosomes, and that HSCs from Ptpn11E76K
mice display altered numbers of centrosomes, leading to abnormal cell division and
genomic instability [63]. These studies bring an important insight into the mechanism of
GOF SHP2 mutant driven leukemogenesis and further our understanding of these
diseases.
While the contribution of GOF SHP2 mutations in mouse models of leukemia has
been studied, no GOF SHP2 mutant mouse model of carcinoma asides from the one
described in this project are currently available. GOF SHP2 mutations are present in a
small percentage of solid cancers, and merit further investigation to determine whether
SHP2 contributes to carcinogenesis and acts as a proto-oncogene in carcinoma.

1.7.3 GOF EGFR mutant lung cancer mouse models
The prevalence of GOF EGFR mutations in patients with NSCLC led to a strong
push to develop transgenic mouse models to study this disease. In 2006, four mouse
models were described by the Wong and Varmus lab, and expressed either the exon 19
LREA deletion Del 747-753, the exon 19 deletion Del 747-752, or the exon 21
EGFRL858R point mutation [139, 140]. All four models used the reverse tetracycline
transactivation system to direct transgene expression. In this system, bitransgenic
animals carry a construct which contains the CCSP promoter and the gene for the
reverse tetracycline transactivator and a construct that contains the gene of interest
under the control of the tetO promoter. When doxycycline is administered to the mice
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either through feed or water, Dox binds to rtTA which can then in turn bind the tetO
promoter and induce expression of the transgene [131]. This system is highly versatile,
and allows for reversible targeted expression of the transgene in a variety of tissue
types depending on the promoter.
Dox induction of bitransgenic CCSP-rtTA/tetO-EGFRDel 747-753, CCSP-rtTA/tetOEGFRDel 747-752, CCSP-rtTA/tetO-EGFRL858R mice led to formation of hyperplastic lesions
with progression to adenocarcinoma at later time points. Tumor burden could be cleared
by Dox withdrawal, treatment with Erlotinib or with Cetuximab, demonstrating that tumor
cells are dependent on sustained GOF EGFR mutant signaling for survival [139, 140].
These transgenic mouse models provide an excellent tool to better understand the
mechanisms of GOF EGFR mutant driven lung carcinogenesis and to identify novel
therapeutic targets and mechanisms of drug resistance [141-143].

1.8 Introduction conclusions
The functions of the protein tyrosine phosphatase SHP2 and its role in cancer
have been extensively studied since its discovery. SHP2 is a well established
leukemic oncogene and GOF SHP2 mutations cause activation of the Ras/MAPK
and Src cell signaling pathway, which can have a transforming effect in
hematopoietic progenitor cells. The function of SHP2 as a mediator of EGFR cell
signaling has also been researched, and it has become clear that the EGF
receptor relies on SHP2 for signal transduction. GOF EGFR mutations act as
oncogenes in lung epithelial cells and are commonly found in non-smoker and
Asian women afflicted with NSCLC. While several tyrosine kinase inhibitors
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targeting EGFR have been developed to treat patients, the majority acquire drug
resistance and relapse, highlighting an urgent need for the identification of
additional therapeutic targets. Since wild type EGFR relies on SHP2 to promote
cell signaling, it begs the question of whether GOF mutant EGFR also requires
SHP2 to induce and sustain lung tumorigenesis. If GOF EGFR mutants were to
actively rely on SHP2 for cell signaling, targeting SHP2 could provide a useful
alternative to EGFR tyrosine kinase inhibitors and could provide a potential target
for drug development. Several studies have supported this idea, and shown that
SHP2 inhibition in a drug resistant GOF EGFR mutant dependent lung cancer
cell line can significantly decrease cell proliferation [144]. Further work is required
though to confirm these results and validate SHP2 as a therapeutic target in GOF
EGFR mutant dependent lung cancer.
As mentioned earlier, the role of SHP2 as an oncogene in hematopoietic
malignancies has been thoroughly described, but the contributions of GOF SHP2
mutations to carcinogenesis are largely unknown. GOF SHP2 mutations have
been identified in a small percentage of multiple types of carcinoma, notably lung
cancer. GOF SHP2 mutations have been found in every lung cancer subtype.
Given the function of SHP2 as a promoter of cell signaling, it is possible that the
GOF SHP2 mutations found in lung cancer patients are actually contributing to
carcinogenesis, and could provide a novel therapeutic target for drug
development. At this stage, little research has been done to investigate this
hypothesis, so the question remains to be answered.
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Chapter 2: Inhibition of SHP2 impairs oncogenic activity of EGF receptor mutants
in non-small cell lung cancer

2.1 Abstract
Gain of function EGFR mutations have been identified in 15-25% of lung
adenocarcinomas and are targets for therapeutic treatment. EGFR tyrosine kinase
inhibitors elicit a strong initial response, but eventually the majority of patients stop
responding to treatment and relapse. Multiple approaches have been evaluated to
overcome drug resistance, but there is still an urgent need for the identification of novel
therapeutic targets to treat lung cancer. SHP2 is an important mediator of EGFR signal
transduction, and positively regulates the Ras/MAPK and Src signaling pathway. In this
study, we determined whether SHP2 also plays a role in GOF EGFR mutant signaling.
SHP2 inactivation using the SHP2 PTP inhibitor SPI-112me, a dominant negative SHP2
mutant, or SHP2 knock-down suppressed cell proliferation and Ras/MAPK signaling in
GOF EGFR mutant dependent HCC827 and H1975 lung cancer cells. To asses the role
of SHP2 in a mouse model of EGFR driven lung cancer, we generated a Dox inducible
transgenic mouse model which expresses the dominant negative PTP-defective
SHP2CSDA mutant in type II pneumocytes under the control of the Clara cell secretory
protein promoter. Dox induced bitransgenic CCSP-rtTA/tetO-EGFRL858R mice exhibited
higher levels of pSrc and pErk1/2 compared to wild type controls. SHP2CSDA expression
in tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice suppressed activation
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of both kinases. Importantly, SHP2CSDA expression significantly delayed EGFRL858R
induced tumor formation and progression. SHP2CSDA expression also reduced pGab1
levels and caused a dissociation of the Gab1/SHP2 complex. This can explain the
decreased phosphorylation of pErk1/2 and Src seen in tritransgenic mice, and could be
the mechanism of action of SHP2CSDA. These results indicate that SHP2 activity is
critical for GOF EGFR mutant mediated tumorigenesis, and establish SHP2 as a
potential therapeutic target in NSCLC.

2.2 Introduction
Lung cancer is the most prevalent type of cancer in the United States. The American
Cancer Society estimates there will be about 224,210 new cases in 2014, leading to
approximately 159,260 deaths (about 27% of all cancer deaths). Despite extensive
research to develop novel therapeutic treatments and to improve understanding of the
biology of this disease, the mortality rate for lung cancer remains high. This is partly
caused by diagnosis at an advanced stage which limits treatment options and by patient
relapse after therapeutic intervention [145, 146]. Lung cancer is divided in several
subtypes, with NSCLC making up about 80% of all cases. NSCLC are further classified
into three groups, adenocarcinoma, large cell carcinoma, and squamous cell carcinoma.
Adenocarcinoma is often initiated by the activation of a single oncogene. Kras, Alk, and
EGFR are the most commonly identified drivers of adenocarcinoma (Fig. 5) [147, 148].
In this study, we focused on GOF EGFR mutant dependent lung cancer. According to
the COSMIC database about 27.54% of lung cancers carry GOF EGFR mutations.
Although patients initially respond to EGFR tyrosine kinase inhibitor treatment, most of
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them relapse and develop drug resistance through multiple mechanisms, including
acquisition of the “gatekeeper” T790M mutation in about 50% of cases [149]. This
mutation alters the conformation of the ATP binding pocket and interferes with Gefitinib
and Erlotinib binding while significantly increasing the affinity of EGFR for ATP. Despite
the development of second and third generation tyrosine kinase inhibitors that
overcome the effects of the T790M gatekeeper mutation, disease progression still
occurs through acquisition of additional drug resistance mechanisms [124]. These
observations highlight an urgent need for the identification of new therapeutic targets to
treat GOF EGFR mutant dependent lung cancer patients.
SHP2 is a cancer essential gene in multiple cancer types and is required to promote
cell transformation, survival, growth and metastasis [55, 57]. SHP2 is an important
component of the EGFR signaling pathway as well. Previous work has shown that
deletion of the N-SH2 binding domain blocks SHP2 relocation to the cell membrane
leading to decreased activity of the Raf and Mek kinases following EGF stimulation
[150]. Moreover, SHP2 knock-down in lung cancer cell lines expressing wild type EGFR
also decreases basal levels of pErk1/2 [151]. The importance of SHP2 in EGFR
mediated signal transduction led us to investigate whether SHP2 activity is also required
to promote GOF EGFR mutant signaling and if targeting SHP2 could negatively impact
cell growth and survival. To answer these questions, we used an in vitro approach to
evaluate the effects of SHP2 knock-down or inhibition on cell signaling and proliferation
in GOF EGFR mutant dependent lung cancer cell lines. We also took advantage of the
existing EGFRL858R transgenic mouse model to test the effects of a dominant negative
PTP-inactive mutant of SHP2 (SHP2CSDA) on tumor onset and progression in vivo [140].
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2.3 Material and Methods
2.3.1 Transgenic mice
2.3.1.1 Construction of L3/L2-tetO vector
The L3/L2-tetO vector was constructed by Dr Noreen Luetteke at the Moffitt Cancer
Center Transgenic Animal Core using the transgenic vector tet-op-mp1 as a backbone.
This vector was kindly provided by Dr. Katerina Politi and contains the tetO promoter,
the mouse protamine1 intron and the polyadenylation sequences [140]. Two tandem
repeats of the 1.2 Kb chicken beta globin insulator (cHS4) were subcloned into the XhoI
site upstream of the tetO response element to limit the risk of leaky transgene
expression [152]. The heterotypic loxP sites were synthesized as oligonucleotides
based on published sequences and annealed to produce double-stranded adaptors with
compatible overhangs to permit subcloning into restriction sites and facilitate screening
[133]. The L3 mutant loxP adaptor contains 5’ XhoI and 3’ SalI sticky ends and was
subcloned into the XhoI site upstream of the cHS4 insulators. The L2 wild-type loxP
adaptor contains 5’ NotI and 3’ EagI sticky ends and was subcloned in reverse
orientation into the NotI site of the tet-op-mp1 vector downstream of the polyA signal.
The integrity and orientation of the loxP sites in the final vector (L3/L2-tetO) were
confirmed by DNA sequencing.

2.3.1.2 Transgene microinjection
The DNA fragment containing the human SHP2CSDA mutant was previously
described and excised from a pCDNA3.1 vector and subcloned into the EcoRV site
between the tetO and polyA sequences of L3/L2-tetO plasmid [34]. The completed
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SHP2CSDA transgene was excised from the vector by digestion with BssHII and isolated
by agarose gel electrophoresis followed by EluTrap electroelution and EluTip
purification. Ethanol precipitated DNA was resuspended in sterile microinjection buffer
(10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5) and microinjected at 3 ng/ µl into 0.5 dpc
fertilized FVB/N zygotes per standard methods. Zygotes were then surgically implanted
into the oviducts of 0.5 dpc pseudopregnant CD-1 females. Offspring were tail biopsied
at weaning and genotyped by PCR and slot blot hybridization to identify transgenic
lines. This work was performed by Dr. Liwei Chen and Jie Wu from the Wu laboratory
and the Moffitt Cancer Center Transgenic Core.

2.3.1.3 Genotyping of tetO-SHP2CSDA transgenic mice
TetO-SHP2CSDA mice were genotyped by PCR using the GoTaq® Hot Start Green
Master Mix (Promega) and the following primers: SHP2T1, 5’AGACGCCATCCACGCTGTTTTGAC-3’ and SHP2T2, 5'TCTCTTTTAATTGCCCGTGATGTT-3’. PCR reaction was performed in a total volume
of 25 µL using the following conditions: 4 min denaturation at 94°C, 35 cycles of 94°C
for 30 sec, 57°C for 30 sec, and 72°C for 30 sec wi th a final extension step of 72°C for 4
min yielding a 430-bp PCR fragment.

2.3.1.4 CCSP-rtTA and EGFRL858R transgenic mice
CCSP-rtTA transgenic mice (in inbred FVB/N background) were provided by Dr.
Jeffrey A. Whitsett. tetO-EGFRL858R mice (in Bl6 background) were obtained from the
NCI/NIH mouse repository. Animals were maintained in pathogen-free housing
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conditions. Rodent chow containing 200 mg/kg Dox (Dox diet, Bio-Serv) was used to
activate the reverse tetracycline transactivator. Animal studies and care were approved
by the Institutional Animal Care and Use Committee of the University of South Florida
and followed institutional and national guidelines.

2.3.2 RT-PCR analysis
Tissue samples were snap frozen in liquid nitrogen. RNA was extracted using Trizol
reagent (Life Technologies) according to manufacturer protocol. Samples were treated
with DNase I (Life Technologies) to avoid DNA contamination. RT-PCR was performed
using the SuperScript One-Step RT-PCR Platinum Taq system (Life Technologies) with
the following primers: SHP2F1: 5'-GGTTGGACAAGGGAATACGG-3’ and SHP2R2: 5'AGGGCTCTGATCTCCACTCG-3’. RT-PCR reaction was performed in a total volume of
50 µL using the following conditions: 30 min cDNA synthesis at 55°C, 4 min
denaturation at 94°C then 35 cycles of 94°C for 30 sec, 57°C for 30 sec, 72°C for 30
sec with a final extension step of 72°C for 4 min y ielding a 462-bp fragment.

2.3.3 Cell cultures and reagents
HCC827 and H1975 cell lines were provided by Dr. Eric Haura and cultured in
complete RPMI medium1640 (10% fetal bovine serum and1% pen strep) purchased
from Life Technologies (Carlsbad, CA) at 37°C in 0. 5% CO2. 293T cells were provided
by Dr. Said Sebti and cultured in complete Dulbecco’s modified eagle medium (DMEM)
(10% fetal bovine serum and1% pen strep) purchased from Life Technologies
(Carlsbad, CA) at 37°C in 0.5% CO 2. The human SHP2CSDA GFP tagged fragment or
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the empty vector control GFP tagged fragment were previously generated in our lab and
excised from the pcDNA3.1 vector then ligated in the pWP1 transfer vector using PmeI
digestion according to established protocols [34]. The SHP2CSDA pWP1 transfer vector,
the packaging plasmid psPAX2 and the enveloped plasmid pMD2.G were transfected in
293T cells plated in a 6cm plate and grown to near confluence for 6 hours in .5 mL
Optimem (Life Technologies) and 2 µL Lipofectamine 2000 (Invitrogen) to obtain
lentivirus. Optimem was removed after transfection and replaced with pen strep free
complete medium. After 48 hours, viral media was collected and filtered using a .45 µm
sterile syringe filter (Corning). HCC827 cells were plated in a 6 well plate and grown to
near confluence. Lentiviral infection was performed in 250 µL pen strep free complete
medium with 750 µL viral media and 40 µg polybrene for 6 hours. Cells were then
washed with PBS (Life Technologies) and grown for 2 weeks in complete medium. The
BD Biosciences FACSVantage DIVA digital cell sorter was used to perform three
rounds of cell sorting two weeks apart from each other to isolate GFP positive HCC827
cells. Percentage of GFP positive HCC827 cells was calculated using the DIVA
software. EGF was purchased from Invitrogen, doxycycline and polybrene from SigmaAldrich, Erlotinib from LC Chemicals, WZ4002 from Selleck, and SPI-112me was
synthesized in-house at the Moffitt Cancer Center.

2.3.4 RNA interference studies
2.3.4.1 siRNA
Cells were plated in 12 well plates (20,000 cells/well) and grown in complete
medium for 48 hours. Cells were transfected with 25 nM PTPN11 On target plus Smart
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Pool siRNA or 25 nM On target plus control pool siRNA (Thermo Scientific Dharmacon)
for 6 hours in 700 µL Optimem with 2 µL Lipofectamine 2000. Optimem was removed
after transfection and cells were grown for 72 hours in complete medium then serum
starved for 16 hours prior to protein extraction.

2.3.4.2 shRNA
The TRIPZ Dox inducible lentiviral human PTPN11 shRNA 1049 and 3469 were
purchased from Open Biosystems. Lentivirus was obtained using 293T cells according
to protocol. HCC827 and H1975 cells were infected with either the 1049 or 3469
lentiviruses and stable clones selected by puromycin treatment. HCC827/1049 and
HCC827/3469 were plated in 6 well plates (100,000 cells/well) and grown in complete
medium for 24 hours. ShRNA expression was induced using 2 µg/mL doxycycline for 96
hours. Cells were then serum starved for 16 hours prior to protein extraction.

2.3.5 Cell proliferation assay
Cell proliferation was measured using the CellTiter-Glo luminescent cell viability
assay (Promega). Cells were plated in 96 well black bottom plates (1000 cells/well) and
grown for 24 hours. HCC827/SHP2CSDA cells and HCC827 SPI-112me treated cells
were grown for 6 days in 200 µL complete medium. SHP2 knock-down using siRNA or
shRNA was adjusted to the 96 well plate format and performed as described earlier in
200 µL complete medium. Cell viability was assayed using 50 µL CellTiter-Glo reagent
and luminescence was measured using a Wallac 1420 Victor plate reader.

34

2.3.6 Soft agar colony formation assay
To perform the soft agar colony formation assay, a 1 mL layer of .8% agar (Fisher
Scientific) in complete medium was poured in each well (6 well plate) and left to solidify
at room temperature for 20 minutes. Next, a 1 mL layer of 0.4% agar in complete
medium containing 10’000 cells was gently poured on top of the bottom layer. All agar
solutions were warmed to 48°C. After solidifying, 5 00 µL of complete medium containing
2 µg/mL doxycycline was added on top of the agar layer. Cells were grown for 21 days
and medium was replaced every four days. The number of colonies was assayed by
MTT staining. 10 mg/mL MTT was added to each well and plate was incubated for 15
minutes at 37°C. A picture of each well was taken u sing an alpha imager and the
number of colonies was counted manually.

2.3.7 Immunoblotting, immunoprecipitation and mass spectrometry analysis
Antibodies to SHP2, Erk1/2, phospho-Erk1/2 (pErk1/2), Gab1, Akt, c-Myc, and βactin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Flag (rabbit),
pGab1 (Y627), Phospho-Akt (pAkt), and phospho-Src (pSrc) antibodies were from Cell
Signaling Technology (Danvers, MA). Src antibody was from Calbiochem (Billerica, MA)
and M2 Flag antibody was from Sigma (St. Louis, MO).
Frozen tissues were crushed and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM Na4P2O7, 1 mM
dithiothreitol, 1 mM Na3VO4, 100 µg/ml of phenylmethylsulfonyl fluoride, 2 µg/ml
leupeptin, 2 µg/ml aprotinin, and 1% Triton X-100). Equal amounts of proteins from
cleared tissue lysates were separated by 10% SDS-polyacrylamide gels and transferred
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to nitrocellulose filters for immunoblotting. Flag-tagged SHP2 was immunoprecipitated
from cleared tissue lysate by using the Flag M2 antibody and Protein-G agarose. Total
EGFR was immunoprecipitated from cleared tissue lysate supernatants by using the
EGFR antibody and Protein-A agarose. Immunoblotting was performed as described
previously [62, 153].
Cells were cultured and cell lysates were prepared for immunoblotting or
immunoprecipitation analyses similar to that described previously [60].
Protein identification by mass spectrometry was performed by the Moffitt Center Center
Proteomics Core using standard procedure. Essentially, tryptic peptides from gel slices
were analyzed with a nanoflow liquid chromatograph coupled to an electrospray ion trap
mass spectrometer for tandem mass spectrometry peptide sequencing. Five tandem
mass spectra were collected in a data-dependent manner following each survey
scan. Sequences were assigned using Mascot (www.matrixscience.com) searches
against mouse or human (for SHP2CSDA) entries. Results from Mascot were compiled in
Scaffold.

2.3.8 Histology and immunohistochemistry
Following euthanasia, mouse lungs were flushed twice with 10 ml PBS and
insufflated with 10% buffered formalin. After fixation overnight in 10% buffered formalin
solution at room temperature, paraffin blocks were prepared by standard procedure by
the Moffitt Cancer Center Tissue Core. Sections (4 µm thick) were stained with
hematoxylin and eosin (H&E) for histological examination.
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2.3.9 Microscopy analysis
Four micron sections of mouse lung tissues were stained with hematoxylin and eosin
and covered in #1.5 cover glass. These slides were used to acquire whole slide images
using the Aperio™ (Vista, CA) ScanScope XT with a 20x/0.8NA objective lens at a rate
of 5 minutes per slide via Basler tri-linear-array. Digital images were stored in the Moffitt
Network Operations Center and accessible to study participants via the password
protected Spectrum (Aperio) web-based interface.
Genie® v1 histology pattern recognition software (Aperio) was used to segment tumor
from other lung tissues and background. This was completed with a training set of 400
iterations and careful pathologist quality control. The resultant tumor region area was
calculated as a percentage of all tissue. This was completed for the isolated tumor
regions using the Aperio Nuclear® v9.1 algorithm with optimized thresholds (Averaging
radius = 1 µm; Segmentation Type = 2 Cytoplasmic Rejection; Threshold Type = 1Edge Threshold with weighted Trimming; Min/ Max Nuc Size = 25 µm2/1000000 µm2/;
RGB stain = 0/ 0.64307/ 0.31756; Positive RGB OD = 0.244583/ 0.509334/ 0.825081).

2.4 Results
2.4.1 SHP2 inhibition decreases cell proliferation and pErk1/2 levels
We selected two cell lines to study the role of SHP2 in GOF EGFR mutant
dependent lung cancer. HCC827 cells carry the LREA deletion in exon 19 and are
sensitive to EGFR tyrosine kinase inhibitors. On the other hand, H1975 cells express
both the EGFRL858R point mutation on exon 21 and the gatekeeper T790M mutation
which confers resistance to Gefitinib and Erlotinib but is sensitive to the irreversible
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EGFR inhibitor WZ4002. These two cell lines enabled us to study the role of SHP2 in
both a drug sensitive and resistant context.
We treated both cell lines with WZ4002 to determine the signaling changes caused
by EGFR inhibition. Since SHP2 lies downstream of EGFR and promotes its signaling
activity, SHP2 inhibition is predicted to show similar changes to those caused by EGFR
inhibition. After 24 hours treatment we detected an increase in p27 and a significant
decrease in pErk1/2, pSrc, pAkt, and c-Myc levels by immunoblot (Fig. 8A). WZ4002
activity was confirmed by checking the phosphorylation levels of EGFR. Treatment
resulted in complete dephosphorylation of the activating Y1080 site of EGFR (Fig. 8B).
We previously described the novel SHP2 inhibitor SPI-112me. This compound binds
the PTP catalytic domain leading to decreased Ras/MAPK signaling and enhanced
STAT1 phosphorylation upon IFNγ stimulation [154]. To determine the effect of SHP2
inhibition on cell viability, we treated HCC827 and H1975 cells with SPI-112me for 6
days. We observed decreased proliferation in both cell lines (Fig. 9). SPI-112me
treatment for 24 hours reduced pErk1/2 levels in both cell lines and pSrc levels in
HCC827 cells, though no major changes were detected in pAkt and pSrc levels (Fig.
10). Since SHP2 inhibition may increase EGFR mediated PI3K pathway activation, we
did not expect to see a decrease in Akt activity in our cells [49, 50]. On the other hand,
while SHP2 is involved in EGFR mediated Src activation; it is possible that in H1975
cells GOF EGFR mutant can activate Src through an alternative pathway, thus SHP2
inhibition would not result in lowered pSrc levels.
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Figure 8. WZ4002 treatment decreases cell signaling and pEGFR levels. HCC827 and
H1975 cells were plated in 6 well plates and grown to confluence in complete medium
then serum starved for 16 hours. Cells were treated with indicated concentrations of
WZ4002 in complete medium for 24 hours followed by protein extraction. (A)
Immunoblot was performed with indicated antibodies after 10% SDS-polyacrylamide gel
separation. (B) 1mg protein from cleared lysate was immuno-precipitated using EGFR
antibody and Protein-A agarose beads. Immunoblot was performed with indicated
antibodies.
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Figure 9. SPI-112me treatment decreases cell proliferation. HCC827 and H1975 cells
were plated in 96 well plates (1000 cells/well), rested overnight, then treated with
indicated SPI-112me concentrations for 6 days in complete medium. Cell proliferation
was assayed using the CellTiter-Glo reagent. Graph values represent an average of
four independent experiments.

Figure 10. SPI-112me treatment decreases pErk1/2 levels. HCC827 and H1975 cells
were plated in 6 well plates (200,000 cells/well) and rested overnight in complete
medium. After 16 hours serum starvation, cells were treated with indicated SPI-112me
concentrations in complete medium for 24 hours followed by protein extraction.
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Immunoblot was performed with indicated antibodies following 10% SDSpolyacrylamide gel separation.

2.4.2 SHP2 knock-down by shRNA decreases cell proliferation and signaling
To confirm that SHP2 inhibition can decrease GOF EGFR mutant mediated cell
proliferation and signaling, we generated two HCC827 cell lines which stably express
either the SHP2 shRNA construct 1049 or 3469 upon Dox induction. SHP2 knock-down
in HCC827/1049 and HCC827/3469 cells resulted in a significant decrease in cell
viability and soft agar colony formation compared to uninduced controls (Fig 11A, B).
To determine whether SHP2 can specifically inhibit EGF induced cell growth, we
serum starved HCC827/1049 cells for 72 hours then stimulated cells with EGF for an
additional 72 hours. Cell proliferation was significantly lower than controls (Fig. 11C)
indicating SHP2 knock-down can specifically decrease EGFR mediated cell proliferation
upon EGF stimulation. The decrease in cell viability seen in HCC827/1049 and
HCC827/3469 cells is correlated with reduced levels of pErk1/2 and c-Myc caused by
SHP2 knock-down (Fig. 11D). Similar results were not obtained in H1975 cells because
the efficiency of SHP2 knock-down was poor, and no signaling changes or decrease in
cell proliferation were detectable following Dox induction (data not included).

2.4.3 SHP2 knock-down by siRNA decreases cell proliferation and signaling
To confirm the results obtained in the previous section using HCC827/1049 and
HCC827/3469 cells and to check whether SHP2 knock-down can overcome GOF EGFR
mutant signaling in the drug resistant H1975 cell line we used a siRNA approach. SHP2
targeted siRNA transfection efficiently knocked-down SHP2 levels in both cell lines, and
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led to a significant decrease in cell proliferation and levels of pErk1/2 and c-Myc.
Transfection of both cell lines using a non-silencing control siRNA did not cause any
visible changes. (Fig. 12A, B).

Figure 11. SHP2 knock-down by shRNA decreases cell proliferation and signaling. (A)
HCC827/1049 and HCC827/3469 cells were plated in 96 well plates and grown for 6
days in complete medium with or without 2µg/mL doxycycline. Cell proliferation was
assayed using the CellTiter-Glo reagent. Graph values represent an average of four
independent experiments. (B) After plating in 0.4% agar in six well plates,
HCC827/1049 and HCC827/3469 cells were grown for 21 days with or without 2µg/mL
doxycycline. Colonies were stained with MTT and counted manually. (C) HCC827/1049
cells were plated in 96 well plates and grown for 3 days in complete medium with or
without 2µg/mL doxycycline. 10ng or 20ng EGF was added at day 3 in serum free
medium. Cell proliferation was assayed 3 days later using the CellTiter-Glo reagent. (D)
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HCC827/1049 and HCC827/3469 cells were plated in 6 well plates (50,000 cells/well)
and grown for 6 days in complete medium with or without 2µg/mL doxycycline followed
by protein extraction. Immunoblot was performed with indicated antibodies following
10% SDS-polyacrylamide gel separation. ( * = p<.0001 as measured using MannWhitney test)

Figure 12. SHP2 knock-down by siRNA decreases cell proliferation and signaling. (A)
HCC827 and H1975 cells were plated in 96 well plates (1000 cells/well) and rested
overnight. Cells were transfected with 25nM non-silencing or SHP2 siRNA in 100µL
Optimem and .5 µL Lipofectamine 2000 for 6 hours. Cells were then grown for 72 hours
in complete medium. Cell proliferation was assayed using the CellTiter-Glo reagent.
Graph values represent an average of two independent experiments (B) HCC827 and
H1975 cells were plated in 12 well plates (20,000 cells/well) and rested overnight. Cells
were transfected with 25nM non-silencing or SHP2 siRNA for 6 hours in 700µL
Optimem with 2µL Lipofectamine 2000. Optimem was removed after transfection and
cells were grown for 72 hours in complete medium then serum starved for 16 hours
prior to protein extraction. Immunoblot was performed with indicated antibodies after
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10% SDS-polyacrylamide gel separation. (P - parental, NS - non-silencing) (* = p<.0001
as measured using Mann-Whitney test)

2.4.4 Expression of a dominant negative SHP2 mutant decreases cell proliferation and
signaling
Previous work has shown that different domains of SHP2 play distinct regulatory
functions [155]. The previous siRNA and shRNA knock-down experiments describe an
important role for SHP2 in GOF EGFR mutant mediated signal transduction, but the
drawback of this approach is the removal of the entire SHP2 protein. In that case, it is
unclear whether the changes seen are caused by absence of the PTP catalytic function
or by a secondary function of SHP2. To address this issue, we generated HCC827 cells
that stably express the dominant negative SHP2 mutant SHP2CSDA. The PTP domain of
this mutant is catalytically inactive while the rest of the protein is intact. When expressed
in cells, SHP2CSDA competes with endogenous wild type SHP2 for substrate binding and
decreases the positive regulatory effects of SHP2 [156]. SHP2CSDA expression in
HCC827 cells caused a small but significant decrease in cell proliferation and levels of
pErk1/2 (Fig. 13A, B). The mild effect of SHP2CSDA on cell viability is most likely caused
by failure of the SHP2 mutant to fully out-compete endogenous SHP2 for substrate
binding. Indeed, despite three rounds of cell sorting HCC827 cells still only expressed
small amounts of the dominant negative SHP2CSDA mutant (Fig. 13B). These results do
confirm though that intact PTP catalytic function is required to promote GOF EGFR
mutant signal transduction and that the changes in cell signaling are most likely not
caused by a secondary function of SHP2.
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Figure 13. Expression of a dominant negative SHP2 mutant decreases cell proliferation
and signaling. (A) HCC827 cells were plated in 96 well plates (1000 cells/well) and
grown in complete medium for 6 days. Cell proliferation was assayed using the
CellTiter-Glo reagent. Graph values represent an average of four independent
experiments (B) HCC827 cells were plated in 6 well plates (200,000 cells/well) and
grown in complete medium for 48 hours before protein extraction. Immunoblot was
performed with indicated antibodies following 10% SDS-polyacrylamide gel separation.
(P - Parental, EV - empty vector, CSDA - SHP2CSDA) ( * = p<.002 as measured using
Mann-Whitney test)

2.4.5 Characterization of the Dox inducible CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA
transgenic mouse model
After concluding our in vitro studies, it became evident that SHP2 activity is indeed
required for cell survival and growth of GOF EGFR mutant dependent lung cancer cell
lines, regardless of T790M mutation presence. SHP2 inactivation by knock-down,
inhibition, or dominant negative SHP2 mutant expression significantly reduced cell
proliferation and activation of the Ras/MAPK pathway. To verify these results and test
whether targeting SHP2 is relevant to GOF EGFR mutant driven lung cancer in vivo, we
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generated a novel tetO-SHP2CSDA Dox inducible transgenic mouse model which
expresses the SHP2CSDA mutant under the control of the tetO promoter (Fig. 14A).

Figure 14. PCR analysis to identify tetO-SHP2CSDA founder lines. (A) The tetOSHP2CSDA construct contains 2 chicken beta globin insulators upstream of the tetO
promoter and a mouse protamine 1 poly-adenylation tail. The tetO-EGFRL858R construct
expresses the GOF EGFRL858R mutant under the control of the tetO promoter. The
CCSP-rtTA construct directs expression of the reverse tetracycline transactivator in type
II pneumocytes under the control of the Clara cell secretory protein promoter. (B) PCR
analysis using DNA extracted from tail snips to identify positive founder lines.

Transgenic mice were obtained by microinjecting the DNA fragment containing the
tetO-SHP2CSDA cassette into zygotes from FVB/N mice and growing the embryos in
pseudo-pregnant CD-1 mice. After two rounds of DNA microinjection, we obtained nine
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founder lines (Line 61, 65, 669, 674, 676, 374, 382, 389, and 390) exhibiting germline
transmission of the transgene (Fig. 14B). Unfortunately, line 61, 65, 674, 374, 382, and
390 displayed leaky transgene expression at the mRNA and protein levels in lung tissue
(Fig. 15). Based on these results, we selected line 669 and line 65 for further study.

Figure 15. Founder line leaky expression check. Lungs were collected from wild type
and monotransgenic tetO-SHP2CSDA mice and snap frozen in liquid nitrogen. Total lung
tissue was split in two. Half was used for RNA extraction, half for protein extraction. RTPCR was performed according to protocol. SHP2CSDA was immunoprecipitated using
Flag tag antibody and Protein-G agarose beads. Immunoblot was performed using Flag
antibody following 10% SDS-polyacrylamide gel separation.
We bred bitransgenic CCSP-rtTA/tetO-SHP2CSDA mice to direct expression of the
transgene to lung epithelial cells (abbreviated C/65 and C/669). After one month of Dox
induction, SHP2CSDA expression was almost tripled in the lungs of C/65 mice and was
also detectable in the lungs of C/669 mice (Fig. 16). We decided to include line 65
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despite its leakiness (Fig. 17A) because of its high expression of the SHP2CSDA
transgene (Fig. 17B). Line 669 does not exhibit leaky expression (Fig. 17A) but
transgene expression is low (Fig. 17B), so it might have a more moderate effect on
GOF EGFR mutant signaling.

Figure 16. Dox induction triggers SHP2CSDA expression in the lungs of bitransgenic
CCSP-rtTA/tetO-SHP2CSDA mice. Lungs were collected from Dox induced/uninduced
bitransgenic and wild type mice and snap frozen in liquid nitrogen. Total lung tissue was
split in two. Half was used for RNA extraction, half for protein extraction. RT-PCR was
performed according to protocol. SHP2CSDA was immunoprecipitated using Flag tag
antibody and Protein-G agarose beads. Immunoblot was performed using Flag antibody
following 10% SDS-polyacrylamide gel separation. (WT - wild type, B - bitransgenic
CCSP-rtTA/tetO-SHP2CSDA)
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Figure 17. Comparison of SHP2CSDA transgene levels and leaky expression between
founder line 669 and 65. (A) Multiple organs were collected from monotransgenic tetOSHP2CSDA mice from line 65 or 669. RNA was extracted using Trizol and RT-PCR
performed according to protocol. (B) SHP2CSDA transgene levels of founder line 65 and
669 were checked at the DNA level using slot-blot hybridization. Founder lines lacking
the SHP2CSDA transgene were used as negative controls. (Br - Brain, Lu - Lung, Li Liver, Sp - Spleen, Ki - Kidney, In - Intestine, Co - Colon)

We also obtained an additional transgenic mouse line which expresses the
EGFRL858R mutant under the control of the tetO promoter (Fig. 14A). When Dox is
administered to CCSP-rtTA/tetO-EGFRL858R bitransgenic mice, the GOF EGFR mutant
is expressed in type II lung pneumocytes and induces epithelial cell transformation.
Within a few weeks of Dox induction, the mice develop diffuse hyperproliferative lesions
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which progress to a more aggressive phenotype with the formation of multifocal
adenomas. Dox withdrawal results in tumor regression, highlighting a dependence on
sustained EGFRL858R expression for tumor survival [140]. We bred our bitransgenic mice
to the EGFRL858R mice to generate tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetOSHP2CSDA mice (abbreviated C/EGFR/65 for founder line 65 and C/EGFR/669 for
founder line 669). Dox induction triggered expression of both transgenes in the lungs of
tritransgenic mice (Fig. 18).

Figure 18. Dox induction triggers SHP2CSDA and EGFRL858R expression in the lungs of
tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Lungs were collected
from tritransgenic mice after 0, 2 and 4 weeks of Dox induction. Total lung tissue was
split in two. Half was used for RNA extraction, half for protein extraction. RT-PCR was
performed according to protocol. SHP2CSDA was immunoprecipitated using Flag tag
antibody and Protein-G agarose beads. Immunoblot was performed using indicated
antibodies following 10% SDS-polyacrylamide gel separation.
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2.4.6 SHP2CSDA expression counters EGFRL858R mediated kinase activation
After characterization of our transgenic mouse models, we fed CCSP-rtTA/tetOEGFRL858R/tetO-SHP2CSDA, CCSP-rtTA/tetO-EGFRL858R, and wild type mice Dox diet for
4, 6, and 8 weeks. EGFRL858R expression increased Erk1/2 and Src activity as indicated
by higher levels of pErk1/2 T202/Y204 and pSrc Y416 in the lungs of bitransgenic mice
compared to wild type controls (Fig. 19). As expected, SHP2CSDA expression countered
the EGFR mutant induced pErk1/2 increase. Interestingly, the SHP2 mutant also
reduced pSrc levels in both tritransgenic line and pAkt levels in C/EGFR/669 mice (Fig
19). It is possible that expression of the SHP2CSDA mutant is higher in the lungs of
tritransgenic mice than in our HCC827/SHP2CSDA cell culture model, and can better outcompete endogenous SHP2 for substrate binding resulting in a stronger impact on
EGFRL858R mediated signal transduction.

2.4.7 SHP2CSDA expression decreases EGFRL858R mediated tumor onset, progression
and burden
As described earlier, bitransgenic CCSP-rtTA/tetO-EGFRL858R mice develop a
diffuse form of adenocarcinoma within four weeks of Dox induction. At later time points,
the disease progresses to a more aggressive phenotype and mice develop multifocal
adenomas. Dox induced SHP2CSDA expression in tritransgenic CCSP-rtTA/tetOEGFRL858R/tetO-SHP2CSDA mice still triggered cellular transformation, but tumor areas
were smaller and more restricted compared to bitransgenic controls (Fig. 20A).
Moreover, SHP2CSDA expression seemed to prevent progression of the disease to a
more aggressive phenotype since few adenomas were detected (Fig. 20A).
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Figure 19. Signaling changes caused by SHP2CSDA expression in CCSP-rtTA/tetOEGFRL858R/tetO-SHP2CSDA mice. Lungs were collected and snap frozen in liquid
nitrogen from wild type, bitransgenic CCSP-rtTA/tetO-EGFRL858R, and tritransgenic
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice after 4, 6, and 8 weeks of Dox
induction. Immunoblot was performed using indicated antibodies following 10% SDSpolyacrylamide gel separation.
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To compare tumor burden in bitransgenic versus tritransgenic animals, we
collaborated with the Moffitt Cancer Center Microscopy Core to design a computer
algorithm that objectively quantifies the percentage of healthy epithelial cells and tumors
cells in lungs using H&E slides. The software was trained to differentiate between
different cell types to calculate the percentage of tumor cells in the mouse lungs. The
results of the analysis are an average of three H&E slides per animal representing
about half of the total lung volume. SHP2CSDA expression significantly decreased tumor
burden in C/EGFR/65 and C/EGFR/669 mice starting at week 4 of Dox induction
compared to C/EGFR mice (Fig. 20B, Table 1). These results confirm that SHP2 also
plays an important role in mediating the tumorigenic activity of the GOF EGFRL858R
mutant in vivo, and reinforce the validity of SHP2 as a potential therapeutic target in
GOF EGFR mutant dependent lung cancer.

Table 1. P-values for tumor burden of tritransgenic mice compared to bitransgenic mice
Time
Time
point
Line
n p-value
point
Line
n
p-value
C/EGFR
5
C/EGFR
7
Week 6 C/EGFR/65 10 0.0001
Week 2
C/EGFR/65
4 0.6889
C/EGFR/669 6 0.0001
C/EGFR/669 5 0.1767
C/EGFR
5
C/EGFR
11
Week 4
Week 8 C/EGFR/65 10 0.0003
C/EGFR/65
5 0.0034
C/EGFR/669 6 0.0007
C/EGFR/669 10 0.0024

P-values were calculated using an unpaired parametric t-test with Welch’s correction
comparing results of either C/EGFR/65 mice to C/EGFR mice or C/EGFR/669 mice to
C/EGFR mice for each time point.
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Figure 20. SHP2CSDA expression decreases EGFRL858R mediated tumorigenesis. (A)
Lungs were collected from wild type, CCSP-rtTA/tetO-EGFRL858R, and CCSP-rtTA/teOEGFRL858R/tetO-SHP2CSDA mice, flushed with PBS then insufflated and fixed overnight in
10% buffered formalin. Lungs were processed by the Moffitt Cancer Center Histology
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Core. (B) Three H&E slides per mice were scanned using the Aperio™ ScanScope XT
and analyzed using a custom algorithm designed using the Genie® v1 histology pattern
recognition software by the Moffitt Cancer Center Microscopy Core.

2.4.8 GOF EGFR mutations induce Gab1 phosphorylation and association with SHP2
After establishing the importance of SHP2 in GOF EGFR mutant dependent lung
cancer, we next investigated how SHP2CSDA decreases tumor burden and signaling in
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. We performed a mass spectrometry
analysis to determine the binding partners of SHP2CSDA in the lungs of tritransgenic
mice (Fig. 21, Table 2). One of the top candidates was Gab1, which is a well known
binding partner of SHP2 [34, 35].

Figure 21. Mass Spectrometry analysis of SHP2CSDA binding partners in the lungs of
CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Protein was extracted from the lungs
of three CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice and combined in one sample.
10mg protein was immunoprecipitated using Flag antibody and Protein-G agarose
beads. Immunoblot was performed using PY20 antibody following 10% SDSpolyacrylamide gel separation. Gel slices corresponding to phosphorylated bands on
immunoblot were cut out and analyzed by mass spectrometry.

55

Table 2. SHP2CSDA bound proteins identified by mass spectrometry.
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Table 2. Continued

Table contains top candidates with a minimum of 3 matching peptides. Protein
identification by mass spectrometry was performed by the Moffitt Cancer Center
Proteomics Core. Tryptic peptides from gel slides were analyzed with a nanoflow liquid
chromatograph coupled to an electrospray ion trap mass spectrometer for tandem mass
spectrometry peptide sequencing. Five tandem mass spectra were collected in a datadependent manner following each survey scan. Sequences were assigned using
Mascot (www.matrixscience.com) searches against mouse entries. (M.W.-Molecular
weight is an approximation, not exact value)

To assess the role of Gab1 in GOF EGFR mutant dependent lung cancer, we
started by checking its phosphorylation status in our HCC827 and H1975 cells and
found that Gab1 is indeed phosphorylated in these cell lines (Fig. 22A). We then treated
both HCC827 and H1975 cells with Erlotinib. In HCC827 cells, EGFR inhibition resulted
in decreased levels of pGab1, concurrent with a dissociation of the Gab1/SHP2
complex (Fig. 22A). These results indicate that SHP2/Gab1 association is directly
promoted by GOF EGFR mutant signaling. Since H1975 cells express the drug resistant
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T790M mutation, Erlotinib treatment should have no effect on these cells. As expected,
Erlotinib treatment of H1975 cells did not affect Gab1/SHP2 association and only
slightly decreased Gab1 phosphorylation at the highest concentration (Fig. 22A).

Figure 22. GOF EGFR mutant mediated Gab1 phosphorylation and Gab1/SHP2
association is disrupted by EGFR inhibition in EGFR dependent lung cancer cell lines.
(A) HCC827 and H1975 cells were plated in 10cm plates in complete medium and
grown to near confluence. Cells were treated with indicated concentration of Erlotinib for
24 hours before protein extraction. Immunoprecipitation was done using 1mg protein,
Gab1 antibody and Protein-G agarose beads. Immunoblot was performed using
indicated antibodies following 10% SDS-polyacrylamide gel separation. IP-IB and
western blot data was obtained from the same cell lysate per sample. (B) The same
procedure described in (A) was used, except cells were treated with WZ4002 instead.
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To further confirm our results, we then treated both cell lines with the EGFR inhibitor
WZ4002 which overcomes the drug resistant T790M mutation. In this case, both cell
lines showed a significant decrease in pGab1 levels and association of Gab1 and SHP2
(Fig. 22B). These results indicate GOF EGFR mutant phosphorylates Gab1 then
recruits and activated SHP2 which in turn positively regulates EGFR signal
transduction.
Based on our in vitro results we wondered whether a similar pattern of SHP2
activation takes place in our bitransgenic CCSP-rtTA/tetO-EGFRL858R mice. We
detected increased levels of pGab1 and Gab1/SHP2 association in C/EGFR mice
compared to wild type controls (Fig 23). Interestingly, SHP2CSDA expression in
C/EGFR/65 and C/EGFR/669 mice significantly decreased pGab1 levels leading to
dissociation of the Gab1/SHP2 complex (Fig 23), potentially revealing the mechanism
by which SHP2CSDA decreases GOF EGFR mutant mediated Ras/MAPK and Src
pathway activation.

Figure 23. EGFRL858R mediated Gab1 phosphorylation and Gab1/SHP2 association is
disrupted by SHP2CSDA expression in the lungs of tritransgenic mice. Protein was
extracted from mouse lungs. Immunoprecipitation was performed using 1mg protein,
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Gab1 antibody and Protein-G agarose beads. Immunoblot was performed using
indicated antibodies following 10% SDS-polyacrylamide gel separation. IP-IB and
western blot data was obtained using the same cell lysate per sample. (WT - wild type,
B - bitransgenic CCSP-rtTA/tetO-EGFRL858R, 669 - C/EGFR/669, 65 - C/EGFR/65)

2.5 Discussion
The EGFR oncogene is a well described driver of lung tumorigenesis and an
established therapeutic target in a molecularly defined subset of NSCLC [157]. Multiple
successful approaches have been developed to target GOF EGFR mutants including
small tyrosine kinase inhibitors and monoclonal antibodies [158, 159]. Unfortunately, the
majority of patients relapse, and develop tumors that no longer respond to EGFR
tyrosine kinase inhibition [160]. Drug resistance is achieved by lung cancer cells through
multiple mechanisms including the acquisition of secondary EGFR mutations, c-Met
amplifications, and others [120-123]. While second and third generation tyrosine kinase
inhibitors are being developed, it is obvious that solely targeting EGFR is not sufficient
to treat patients with recurrent tumors [67, 124]. These observations highlight an urgent
need for the identification of additional therapeutic targets for the treatment of GOF
EGFR mutant NSCLC patients.
Previous work has shown that SHP2 is a key downstream effector of EGFR signal
transduction [34, 57]. EGFR activation recruits SHP2 to the cell membrane where it
becomes activated and positively regulates the Ras/MAPK and Src signaling pathways
through multiple mechanisms [36, 42, 44]. The importance of SHP2 in EGFR signal
transduction led us to inquire whether SHP2 is also required by GOF EGFR mutants
and could potentially serve as a therapeutic target in GOF EGFR mutant dependent
NSCLC.
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To determine whether targeting SHP2 impacts cell proliferation and survival in both
a drug sensitive or resistant context, we selected the HCC827 and H1975 lung cancer
cell lines for our experiments. HCC827 cells respond to EGFR inhibition while H1975
cells carry the gatekeeper mutation T790M and are resistant to Erlotinib. SHP2
inhibition using the SPI-112me inhibitor decreased cell proliferation and pErk1/2 levels.
Similarly, SHP2 knock-down using shRNA or siRNA also decreased cell viability, colony
formation, and Ras/MAPK signaling in both GOF EGFR mutant dependent lung cancer
cell lines. These results demonstrate that SHP2 function is required to mediate cell
signaling and demonstrate a key role for SHP2 in cell growth of both drug resistant and
sensitive lung cancer cells. To check whether intact SHP2 PTP catalytic activity is
necessary to mediate GOF EGFR mutant signal transduction, I expressed the dominant
negative SHP2CSDA mutant in HCC827 cells and observed a decrease in cell
proliferation and Erk1/2 activation. This data indicate that intact PTP catalytic function is
indeed required to mediate GOF EGFR mutant signaling.
In the next step of our study, we decided to test our hypothesis in vivo. We
generated a novel Dox inducible tetO-SHP2CSDA transgenic mouse model which
expresses the dominant negative SHP2CSDA mutant under the control of the tetO
promoter in lung epithelial cells. We also obtained a second transgenic mouse model
that expresses the EGFRL858R mutant under the control of the tetO promoter. We then
bred bitransgenic CCSP-rtTA/tetO-EGFRL858R and tritransgenic CCSP-rtTA/tetOEGFRL858R/tetO-SHP2CSDA mice to study the effects of the SHP2CSDA mutant in an
EGFRL858R driven mouse model of lung carcinogenesis. Dox induction of bitransgenic
mice increased pErk1/2 and pSrc levels compared to wild-type controls. SHP2CSDA
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expression countered EGFRL858R mediated kinase activation and significantly reduced
tumor formation and burden in the lungs of tritransgenic mice. The dominant negative
SHP2CSDA mutant also conferred a protective effect by blocking progression of the
disease to a more aggressive phenotype. These results demonstrate that targeting
SHP2 can significantly impact GOF EGFR mutant dependent lung tumorigenesis and
support the validity of SHP2 as a therapeutic target for GOF EGFR mutant dependent
NSCLC.
We performed a mass spectrometry analysis to identify the binding partners of
SHP2CSDA in the lungs of tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice
and determine how SHP2CSDA can decrease cell signaling and tumor growth. The
results of the analysis identified Gab1 as a top candidate. Gab1 is the main docking
protein for SHP2, and association between the two is required for proper SHP2
activation and function [35]. Using our lung cancer cell lines, we determined that EGFR
inhibition decreases Gab1 phosphorylation and disrupts Gab1/SHP2 association.
In our bitransgenic CCSP-rtTA/tetO-EGFRL858R mouse model, we found that EGFRL858R
increases pGab1 levels and Gab1/SHP2 complex formation in the lungs. SHP2CSDA
expression significantly decreases Gab1 phosphorylation and Gab1/SHP2 association.
A possible explanation for this observation is that SHP2 can regulate the activity of its
own docking protein [35, 60]. When SHP2CSDA binds to pGab1, it prevents the activation
of a positive feedback loop and blocks the phosphorylation of additional Gab1 proteins,
thus disrupting Gab1/SHP2WT complex formation and causing the decreases in cell
signaling seen in tritransgenic CCSP-rtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice (Fig.
24).
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Figure 24. SHP2CSDA mechanism of action in CCSP-rtTA/tetO-EGFRL858R/tetOSHP2CSDA mice. GOF EGFRL858R phosphorylates Gab1 and recruits SHP2CSDA which
prevents phosphorylation of additional Gab1 proteins and blocks recruitment of wild
type SHP2 and activation of the Ras/MAPK and Src signaling pathways.

In conclusion, we have described an important function of SHP2 as a key mediator
of GOF EGFR mutant driven lung tumorigenesis and established SHP2 as a potential
therapeutic target for the treatment of GOF EGFR mutant dependent NSCLC.
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Chapter 3: Active SHP2 mutant induces lung hyperproliferative lesions and
adenoma in transgenic mice

3.1 Abstract
SHP2 plays an important role in carcinogenesis. Gain of function SHP2 mutants are
known leukemic oncogenes and have been identified in multiple cancer types, including
lung cancer. However, the oncogenic potential of activating SHP2 mutants in lung
tumorigenesis has not been established. To address this question we generated Dox
inducible bitransgenic CCSP-rtTA/tetO-SHP2E76K mice that express the GOF SHP2E76K
mutant in lung epithelial cells under the control of a rat Clara cell secretory protein
promoter fragment. SHP2E76K expression increased pErk1/2, pSrc, c-Myc and Mdm2
levels in the lungs of bitransgenic mice. After 6 to 9 months of Dox induction,
bitransgenic CCSP-rtTA/tetO-SHP2E76K mice developed atypical adenomatous
hyperplasia that progressed to adenoma and adenocarcinoma in the lungs. These
results demonstrate a new role for this GOF SHP2 mutant as a lung cancer oncogene.
To determine whether tumor survival is dependent on continued SHP2E76K expression,
we analyzed tumor-bearing mice after 1 month of Dox withdrawal by Magnetic
Resonance Imaging (MRI). The results of the MRI analysis indicate that SHP2E76K
expression is required for tumor maintenance in this mouse model of lung
adenocarcinoma. Further study revealed that SHP2E76K expression increased Gab1
phosphorylation and promoted Gab1/SHP2 complex formation in the lungs of
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bitransgenic mice and cancer cell lines. This data indicate that GOF SHP2 mutants
auto-regulate the tyrosine phosphorylation of their own docking protein. Since inhibition
of Src family kinases (SFKs) decreases pGab1 levels in cell lines expressing an
activating SHP2 mutant, and SHP2E76K expression increases Src phosphorylation, it
seems likely that the SFKs are an important mediator of this positive feedback loop
mechanism.

3.2 Introduction
Protein tyrosine kinases have traditionally been identified as inducers of cell
signaling and act as oncogenes when acquiring gain of function mutations [161]. Since
protein tyrosine phosphatases usually counter the biochemical reaction of PTKs, they
have generally been considered tumor suppressors. However, increasing evidence
suggests that some PTPs collaborate with PTKs to promote cell signaling and
transformation [162, 163]. Indeed, tyrosine phosphorylation does not always positively
regulate the target protein. For example, phosphorylation of tyrosine sites such as Src
Y530 or CDK1 Y15 negatively regulates enzyme activity of these kinases [14-16].
On the other hand, phosphorylation of the p120RasGap and c-CBL tyrosine binding
sites upon EGFR activation recruits these negative regulators to the cell membrane and
terminates EGFR signaling [164-166]. In these circumstances, dephosphorylation of the
p120RasGap and c-CBL docking sites and the inhibitory Src Y530 and CDK1 Y15 sites
promotes PTK signal pathway activity. This concept of positive collaboration between
PTKs and PTPs is exemplified by SHP2.
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Indeed, growth factor receptors recruit and activate SHP2 by inducing a
conformational change that relieves its auto-inhibitory mechanism. Active SHP2
promotes Ras/MAPK and Src signaling pathway activation [26, 34, 45]. Because of its
positive regulatory effects on cell signaling, SHP2 is a cancer essential gene in certain
types of carcinoma and is required to maintain cell growth and survival [55, 57].
Moreover GOF SHP2 mutations are known leukemic oncogenes and have been
identified in approximately 35% of juvenile myelomonocytic leukemia, 10% of childhood
myelodysplastic syndromes, 7% of B-cell acute lymphoblastic leukemia, and 4% of
acute myelogenous leukemia [17, 167]. The majority of activating SHP2 mutations are
located in the N-SH2/PTP interface and disrupt the auto-inhibitory mechanism,
conferring constitutive activity to the PTP catalytic domain (Fig. 4) [58]. Activating SHP2
mutations have also been identified in carcinoma at lower rates than in hematologic
malignancies. According to the COSMIC database, as of 4-14-2014, about 1.81% of
lung cancer cases carry GOF SHP2 mutations. Even though this percentage may seem
small, it still represents a large number of people due to the high prevalence of lung
cancer in the population.
The American Cancer Society estimates there will be about 224,210 new cases of
lung cancer in 2014, causing approximately 159,260 deaths (about 27% of all cancer
deaths). Lung cancer is usually initiated by activation of a single oncogene. Kras,
EGFR, and Alk are the most common drivers of lung tumorigenesis [147, 148].
Additional oncogenes such as RIT1 and RET fusions have been identified in a smaller
percentages of cases [168-170]. These genes provide interesting targets for the
development of new drugs that can broaden treatment opportunities for patients. Since
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GOF SHP2 mutations are present in lung cancer, the contribution of SHP2 to
tumorigenesis merits further investigation.
To achieve this goal, we generated a novel Dox inducible mouse model that carries
the GOF SHP2E76K mutant (tetO-SHP2E76K). We bred these mice to a second strain of
transgenic mice which express rtTA under the control of the Clara cell secretory protein
to direct expression of SHP2E76K in type II pneumocytes [131]. The CCSP-rtTA mouse
model has previously been validated as a reliable model of NSCLC [131].

3.3 Material and methods
3.3.1 Transgenic mice
3.3.1.1 Transgene microinjection
The L3/L2-tetO vector was constructed as described in the previous section. The
DNA fragment containing the human SHP2E76K mutant was excised from a pCDNA3.1
vector and subcloned into the EcoRV site between the tetO and polyA sequences of
L3/L2-tetO plasmid [62]. The completed SHP2E76K transgene was excised from the
vector by digestion with BssHII and isolated by agarose gel electrophoresis followed by
EluTrap electroelution and EluTip purification. Ethanol precipitated DNA was
resuspended in sterile microinjection buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.5)
and microinjected at 3 ng/ µl into 0.5 dpc fertilized FVB/N zygotes per standard
methods. Zygotes were then surgically implanted into the oviducts of 0.5 dpc
pseudopregnant CD-1 females. Offspring were tail biopsied at weaning and genotyped
by PCR and slot blot hybridization to identify transgenic lines. This work was performed
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by Dr. Liwei Chen and Dr. Wu from the Wu laboratory and the Moffitt Cancer Center
Transgenic Mouse Model Core.

3.3.1.2 Genotyping of tetO-SHP2E76K transgenic mice
TetO-SHP2E76K mice were genotyped by PCR using the GoTaq® Hot Start Green
Master Mix (Promega) and the following primers: SHP2T1, 5’AGACGCCATCCACGCTGTTTTGAC-3’ and SHP2T2, 5'TCTCTTTTAATTGCCCGTGATGTT-3’. PCR reaction was performed in a total volume
of 25 µL using the following conditions: 4 min denaturation at 94°C, 35 cycles of 94°C
for 30 sec, 57°C for 30 sec, and 72°C for 30 sec wi th a final extension step of 72°C for 4
min yielding a 430-bp PCR fragment.

3.3.1.3 CCSP-rtTA transgenic mice
CCSP-rtTA transgenic mice (in inbred FVB/N background) were provided by Dr.
Jeffrey A. Whitsett. Animals were maintained in pathogen-free housing conditions.
Rodent chow containing 200 mg/kg Dox (Dox diet, Bio-Serv) was used to activate the
reverse tetracycline transactivator. Animal studies and care were approved by the
Institutional Animal Care and Use Committee of the University of South Florida and
followed institutional and national guidelines.

3.3.2 RT-PCR analysis
Tissue samples were snap frozen in liquid nitrogen. RNA was extracted using Trizol
reagent (Life Technologies) according to manufacturer protocol. Samples were treated
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with DNase I (Life Technologies) to avoid DNA contamination. RT-PCR was performed
using the SuperScript One-Step RT-PCR Platinum Taq system (Life Technologies) with
the following primers: SHP2F1: 5'-GGTTGGACAAGGGAATACGG-3’ and SHP2R2: 5'AGGGCTCTGATCTCCACTCG-3’. RT-PCR reaction was performed in a total volume of
50 µL using the following conditions: 30 min cDNA synthesis at 55°C, 4 min
denaturation at 94°C then 35 cycles of 94°C for 30 sec, 57°C for 30 sec, 72°C for 30
sec with a final extension step of 72°C for 4 min y ielding a 462-bp fragment.

3.3.3 Immunoblotting, immunoprecipitation, and mass spectrometry analysis
Antibodies to SHP2, Erk1/2, phospho-Erk1/2, Gab1, Akt, c-Myc, and β -actin were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Flag (rabbit), pGab1 (Y627),
Phospho-Akt, and phospho-Src antibodies were from Cell Signaling Technology
(Danvers, MA). Src antibody was from Calbiochem (Billerica, MA) and M2 Flag antibody
was from Sigma (St. Louis, MO). Antibodies to MDM2 (clone 2A9) and MDMX (clone
8C6) were obtained from Dr. Jiandong Chen and generated as described previously
[171, 172]. The p53 antibody was purchased from IMGENEX (San Diego, CA).
Frozen tissues were crushed and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 25 mM NaF, 5 mM Na4P2O7, 1 mM
dithiothreitol, 1 mM Na3VO4, 100 µg/ml of phenylmethylsulfonyl fluoride, 2 µg/ml
leupeptin, 2 µg/ml aprotinin, and 1% Triton X-100). Equal amounts of proteins from
cleared tissue lysate were separated by 10% SDS-polyacrylamide gels and transferred
to nitrocellulose filters for immunoblotting. Flag-tagged SHP2 was immunoprecipitated
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from cleared tissue lysate by using the Flag M2 antibody and Protein-G agarose.
Immunoblotting was performed as described previously [62, 153].
Hel cells were provided by Dr. Ken Zuckerman and cultured and cell lysates
prepared for immunoblotting or immunoprecipitation analyses similar to that described
previously [62, 153]. Tyrosine kinase inhibitors were from LC Laboratories (Woburn,
MA).
Protein identification by mass spectrometry was performed by the Moffitt Cancer
Center Proteomics Core using standard procedure. Essentially, tryptic peptides from gel
slides were analyzed with a nanoflow liquid chromatograph coupled to an electrospray
ion trap mass spectrometer for tandem mass spectrometry peptide sequencing. Five
tandem mass spectra were collected in a data-dependent manner following each survey
scan. Sequences were assigned using Mascot (www.matrixscience.com) searches
against mouse or human entries. Results from Mascot were compiled in Scaffold.

3.3.4 qRT-PCR
qRT-PCR was performed using Power SYBR Green reagents (Applied Biosystems)
and proprietary primers for 18s rRNA or Mdm2 exon 1-3 from IDT (San Jose, CA).
Samples were assayed in triplicates whereas standards, no amplification controls, and
no DNA controls were performed in duplicates. The ABI PRISM 7900HT Sequence
Detection System from Applied Biosystems was used to run qPCR. Data was
normalized using 18s rRNA as the internal control and analyzed using the SDS software
version 2.3.
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3.3.5 Histology and immunohistochemistry
Mice were euthanized by CO2 asphyxiation followed by cervical dislocation. Lungs
were flushed twice with 10 ml PBS and insufflated with 10% buffered formalin. After
overnight fixation in 10% buffered formalin solution at room temperature, paraffin blocks
were prepared by standard procedure by the Moffitt Cancer Center Tissue Core.
Sections (4µm thick) were stained with hematoxylin and eosin (H&E) for histological
examination.
For IHC analysis of pErk1/2, slides were stained using a Ventana Discovery XT
automated system (Ventana Medical Systems, Tucson). Slides were deparaffinized with
EZ Prep solution (Ventana). Heat-induced antigen retrieval method was used in Cell
Conditioning 1 (Ventana). A rabbit pErk1/2 antibody (#4376, Cell Signaling, Danvers,
MA) was used at a 1:200 dilution in PSS diluent (Ventana) and incubated for 32 min.
Anti-rabbit secondary antibody (Ventana) was used for 20 min. The detection system
used was the Ventana OmniMap kit and slides were counterstained with Hematoxylin.
All slides were scanned and uploaded as digital images using the Aperio™ (Vista, CA)
ScanScope XT with a 20x/0.8NA objective lens at a rate of 5 minutes per slide via
Basler tri-linear-array. Digital images were stored in the Moffitt Network Operations
Center and accessible to study participants via the password protected Spectrum
(Aperio) web-based interface.

3.3.6 MRI analysis
Mice were anesthetized with 2% isoflurane, restrained in a mouse cradle mounted
on an insertion device and positioned within the RF coil of the magnet while
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continuously receiving isoflurane. Respiratory function and temperature of the animals
were monitored and controlled throughout the imaging session using the SAI system
(Small Animal Instruments, Inc.). Temperature control of the animals was achieved by a
variable temperature gas unit and set to maintain a body temperature of 37 ± 1°C.
MRI was performed using a 7-T horizontal magnet (ASR 310, Agilent Technologies)
equipped with nested 205/120/HDS gradient insert and a bore size of 310 mm.
Temperature control of the imaging gradients was achieved by means of a water chiller
(Neslab Waters) and maintained at 12°C for all acqu isitions. Using a 35-mm Litz-cage
coil (Doty Scientific), coronal T2-weighted fast spin-echo (FSE, 3D) sequences were
acquired with TE/TR = 64/1000 ms, Matrix = 256x128x16, field of view (FOV)
=90x45x16 mm and slice thickness of 1 mm over 8.5 minutes. Tumor volumes and
dimensions were quantified by manually drawn regions of interest (ROI) using VnmrJ
(Agilent Technologies, Inc.). MRI was performed by the Moffitt Cancer Center Animal
Imaging Core.
In an initial pilot study, T2-weighted FSEMs sequences were acquired with TR = 954
ms, ESP = 7.5 ms, ETL = 8 (eff. TE = 60 ms), FOV = 40 x 90 mm, Matrix = 128 x 256,
15 slices at 1 mm thickness, 8 averages and fat suppression in 3.75 minutes.

3.4 Results
3.4.1 Generation of Dox inducible tetO-SHP2E76K transgenic mice
We selected the SHP2E76K mutant for our transgenic mouse model because it is a
well characterized leukemic oncogene, confers the highest PTP catalytic activity of
known GOF SHP2 mutants, and has previously been identified in lung cancer patients
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[62, 173]. This point mutation is located in the N-SH2 binding domain and disrupts the
auto-inhibitory mechanism conferring constitutive catalytic activity to the PTP domain
(Fig 25).

Figure 25. Crystal structure of the GOF SHP2E76K mutation (PDB: 2SHP). This structure
is missing the c-terminal tail but otherwise contains the C-SH2 binding domain (yellow),
the N-SH2 binding domain (red) and the PTP catalytic domain (green). The blue residue
highlights the location of the E76K point mutation which disrupts the auto-inhibitory
mechanism.

To generate our transgene, we modified the tetracycline inducible tet-op mp1 vector
by inserting two chicken beta globin insulators upstream of the tetO promoter and
flanking the cassette with a pair of oppositely oriented heterotypic L2 and L3 loxP sites
[133, 152]. The L2/L3 transgenic vector system is capable of undergoing Crerecombinase mediated cassette exchange [133]. We then subcloned a C-terminal Flag
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tagged human SHP2E76K coding sequence downstream of the tetO promoter of our
L2/L3 vector to obtain the tetO-SHP2E76K transgenic construct (Fig. 26A). Transgenic
mice were obtained by microinjecting the DNA fragment containing the tetO-SHP2E76K
cassette into zygotes from FVB/N mice and growing the embryos in pseudo-pregnant
CD-1 mice. We identified eight founder lines (Line 394, 398, 400, 404, 417, 422, 425,
428) that displayed germline transmission of the transgene (Fig. 26B).

Figure 26. Transgenic constructs and founder line identification. (A) The tetO-SHP2E76K
construct contains 2 chicken beta globin insulators upstream of the tetO promoter and a
mouse protamine 1 poly-adenylation tail. The CCSP-rtTA construct directs expression
of the reverse tetracycline transactivator in type II pneumocytes under the control of the
Clara cell secretory protein promoter. (B) PCR analysis using DNA extracted from tail
snips to identify positive founder lines.

We selected founder lines 400, 398, 417 and 425 for further investigation. Founder
line 400 expressed leaky expression of the SHP2E76K transgene at the mRNA level in all
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organs tested (Fig. 27). Based on these results, we selected lines 398, 417, and 425
that displayed no leaky expression for further study (Fig. 27).

Figure 27. Founder line leaky expression check. Lungs were collected from
monotransgenic tetO-SHP2E76K mice and snap frozen in liquid nitrogen. Trizol was used
for RNA extraction and RT-PCR was performed according to protocol. (Lu - lung, Li liver, Ki - kidney, Co - colon)
We bred bitransgenic CCSP-rtTA/tetO-SHP2E76K mice (abbreviated C/398, C/417,
and C/425) and screened for Dox inducible expression of SHP2E76K in the lungs. After
one month of Dox induction, SHP2E76K was readily detectable in the lungs of
bitransgenic mice at the mRNA and protein level (Fig 28).

3.4.2 SHP2E76K expression induces Ras/MAPK and Src signaling pathway activation
After characterizing our transgenic mouse model, we determined the biochemical
changes caused by SHP2E76K expression in the lungs of CCSP-rtTA/tetO-SHP2E76K
mice. SHP2E76K expression increased pErk1/2 T202/Y204 and pSrc Y416 levels but did
not affect pAkt S473 in the lungs of bitransgenic mice compared to wild type controls
75

(Fig. 29). SHP2E76K expression also increased c-Myc levels in the lungs of bitransgenic
mice (Fig. 29). C-Myc is an important promoter of cell proliferation and is a driver
oncogene of lung cancer [153, 174].

Figure 28. Dox induced SHP2E76K expression is detectable in the lungs of bitransgenic
CCSP-rtTA/tetO-SHP2E76K mice. Lungs were collected from Dox induced bitransgenic
and wild type mice and snap frozen in liquid nitrogen. Total lung tissue was split in two.
Half was used for RNA extraction, half for protein extraction. RT-PCR was performed
according to protocol. SHP2E76K was immunoprecipitated using Flag tag antibody and
Protein-G agarose beads. Immunoblot was performed using Flag antibody following
10% SDS-polyacrylamide gel separation.

Previous work has shown that activation of the Ras/MAPK pathway upregulates
Mdm2 which suppresses p53 activity [175]. Experiments performed by Dr. Yuan Ren in
the Wu laboratory have consistently shown that SHP2E76K transformed TF-1 cells and
increased Mdm2 while reducing p53 but did not have any effect on MDMX [60, 62].
Moreover, Ras/MAPK pathway inactivation by the Mek inhibitor U0126 restored Mdm2
to non-transformed levels, indicating that SHP2E76K upregulates Mdm2 through
activation of the Ras/MAPK pathway [60]. To determine whether a similar mechanism of
Mdm2 upregulation is present in our bitransgenic CCSP-rtTA/tetO-SHP2E76K mice, we
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measured Mdm2 mRNA level expression by qRT-PCR. Results showed that Mdm2
mRNA levels are significantly higher in the lungs of bitransgenic mice (n=4) compared
to wild type controls (n=4) (Fig. 30)

Figure 29. Signaling changes caused by SHP2E76K expression in CCSP-rtTA/tetOSHP2E76K mice. Lungs were collected and snap frozen in liquid nitrogen from wild type,
monotransgenic tetO-SHP2E76K, and bitransgenic CCSP-rtTA/tetO-SHP2E76K mice after
1 month of Dox induction. Immunoblot was performed using indicated antibodies
following 10% SDS-polyacrylamide gel separation. (WT - wild type, M - monotransgenic,
B - bitransgenic)
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Figure 30. qRT-PCR analysis of Mdm2 mRNA levels in the lungs of bitransgenic mice
compared to wild type controls. Lungs were collected from wild type or CCSP-rtTA/tetOSHP2E76K mice and snap frozen in liquid nitrogen. RNA was extracted using Trizol
according to manufacturer protocol. qRT-PCR was repeated two times. Lung samples
from each animal was assayed in triplicates (n=4). Average Ct values were 27.5 for WT
and 25.8 CCSP/E76K. Statistical analysis was performed using the non parametric
Mann-Whitney test.

3.4.3 SHP2E76K expression induces hyperplasia and adenoma formation in lung
epithelial tissue
SHP2E76K expression caused significant histological alterations in the lungs of
CCSP-rtTA/tetO-SHP2E76K mice. After 6 months of Dox induction, the majority of
animals displayed extensive atypical adenomatous hyperplasia (n=12) (Fig. 31A). 25%
of bitransgenic mice (n=12) developed adenomas as well, including in one case as early
as 2 months after Dox induction (Fig. 31A). At the 9 months time point, 86.7% of
bitransgenic mice (n=15) developed adenomas that were larger in size and several
animals developed adenocarcinomas (defined by a diameter of ≥5mm) (Fig. 31B) [176].
Histological evaluation by a pathologist indicated that tumors were of papillary, solid, or
mixed subtypes (Table 3) with features resembling human NSCLC.
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In comparison, none of our monotransgenic tetO-SHP2E76K or wild type control mice
developed hyperplasia or adenoma after 6 months of Dox induction (WT, n= 6; E76K,
n=7). At the 9 month time point, 2 control mice developed tumors with similar
histological features to tumors identified in bitransgenic mice (one WT and one E76K),
but they were significantly smaller in size (WT, n= 9; E76K, n=4) (Fig. 30B) At 12
months of Dox induction, two control mice displayed tumors (one WT and one E76K),
one of them had features similar to adenocarcinoma, the other to squamous cell
carcinoma (WT, n= 12; E76K, n=12).
Overall, Dox induced CCSP-rtTA/tetO-SHP2E76K mice developed lung tumors at a
significantly higher rate than monotransgenic tetO-SHP2E76K, CCSP-rtTA, or wild type
controls (Fig. 32) indicating that SHP2E76K promotes lung tumorigenesis with NSCLC
features in this transgenic mouse model of lung cancer.

3.4.4 Dox withdrawal induces lung tumor regression
For the next step of our study, we took advantage of the reversible feature of our
transgenic mouse model and the small animal imaging facilities at the Moffitt Cancer
Center to determine whether constant SHP2E76K expression is required for tumor
maintenance. We set up a small pilot study to determine whether MRI can be used to
detect established tumors in the lung of bitransgenic mice (n=4). Tumor presence was
verified by dissection following positive identification by MRI analysis (Fig. 33). The
results of our pilot study established MRI as a valid technique to detect lung tumors in
vivo.
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Figure 31. Histological evaluation of lung hyperplasia and adenoma formation in CCSPrtTA/tetO-SHP2E76K mice. Lungs were collected from wild type and CCSP-rtTA/tetOSHP2E76K mice, insufflated with 10% neutral buffered formalin, fixed overnight, then
processed by the Moffitt Cancer Center Histology Core. Slides were stained with H&E,
and histological alterations were evaluated by a pathologist (A) Bitransgenic mice
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developed hyperproliferative lesions and small adenomas after 6 months of Dox
induction. (B) Bitransgenic mice developed lung adenomas and adenocarcinomas after
9 months of Dox induction. Only two mice out of 24 control animals developed
adenomas after 9 months of Dox induction.

Table 3. Histological evaluation of tumor subtype.

H&E stained slides from representative lung tumor-carrying CCSP-rtTA/tetO-SHP2E76K
and control mice were evaluated by a resident Moffitt Cancer Center pathologist to
determine the histological subtype of the lesions.
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Figure 32. Kaplan-Meier tumor free survival curves for bitransgenic mice compared to
monotransgenic or wild type controls. The Log rank test was used for statistical analysis
to compare bitransgenic mice to either wild type or monotransgenic controls. Both test
yielded p < 0.0001. (The numbers inside parentheses in graph legend indicate the total
number of mice in each group)

Biochemical analysis confirmed that SHP2E76K expression was no longer detectable
after Dox withdrawal (Fig. 35A). In the absence of the positive regulatory effects of
SHP2E76K, pErk1/2, pSrc, and c-Myc all returned to levels comparable to wild type
controls (Fig. 35B). These results were further supported by IHC staining of lung tissues
with a pErk1/2 antibody. Strong pErk1/2 staining is detectable in SHP2E76K induced lung
tumors (Fig. 35C). After Dox withdrawal, pErk1/2 staining intensity was comparable to
wild type controls (Fig. 35C).
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Figure 33. MRI pilot study. CCSP-rtTA/tetO-SHP2E76K mice were Dox induced for 9
months then imaged by the Moffitt Cancer Center small animals imaging core staff.
Animals with MRI detectable lung tumors were euthanized and dissected to confirm the
presence of tumors in the area seen in MR images. (n=4)

3.4.5 SHP2E76K auto-regulates phosphorylation of its docking protein Gab1
To determine the mechanisms of SHP2E76K driven lung tumorigenesis we sought to
identify the binding partners of SHP2E76K in the lungs of CCSP-rtTA/tetO-SHP2E76K
mice. SHP2E76K immunoprecipitates were obtained from lung tissue of Dox induced
bitransgenic mice, separated on a 10% SDS polyacrylamide gel, and immunoblotted
with a PY20 antibody (Fig. 36 A). Gel bands corresponding to phosphorylated tyrosines
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on immunoblot were analyzed by mass spectrometry. The proteins identified by mass
spectrometry are listed in Table 4. One of the top candidates was Gab1. Further
analysis using co-immunoprecipitation confirmed that Gab1 and the SHP2E76K mutant
associate in the lungs of bitransgenic CCSP-rtTA/tetO-SHP2E76K mice (Fig. 36B).

Figure 34. Dox withdrawal causes lung tumor regression. (A) CCSP-rtTA/tetO-SHP2E76K
mice were Dox induced for 9 months. A first round of MR imaging confirmed presence
of tumors in the lungs of bitransgenic animals. Mice were then placed on regular chow
for a month, and imaged for a second time using similar conditions. (n=6) (B) After the
second round of MRI analysis, bitransgenic mice were sacrificed and lung tissue
84

collected. H&E slides were prepared by the Moffitt Cancer Center Histology Core and
evaluated by a pathologist to check for presence of residual lesions.
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Figure 35. Dox withdrawal abrogates the positive regulatory effects of SHP2E76K in the
lungs of CCSP-rtTA/tetO-SHP2E76K mice. (A) Lung tissue was collected from CCSPrtTA/tetO-SHP2E76K mice following the second round of MRI after 1 month Dox
withdrawal. Tissue was snap frozen in liquid nitrogen and divided in half to extract both
RNA and protein. RT-PCR was performed according to manufacturer’s protocol. Flagtagged SHP2E76K was immunoprecipitated using Flag antibody and Protein-G agarose
beads followed by 10% SDS-polyacrylamide gel separation and immunoblot with Flag
antibody. (B) Lungs were collected from wild type and pre or post Dox induced CCSPrtTA/tetO-SHP2E76K mice. Protein extraction was followed by 10% SDS-polyacrylamide
gel separation and immunoblot with indicated antibodies. (C) Lung slides from pre and
post induction CCSP-rtTA/tetO-SHP2E76K or wild type mice were stained with pErk1/2
antibody. (WT - wild type, B - bitransgenic)

Figure 36. SHP2E76K expression induces Gab1 phosphorylation and Gab1/SHP2
association in the lungs of CCSP-rtTA/tetO-SHP2E76K mice. (A) Protein was extracted
from the lungs of CCSP-rtTA/tetO-SHP2E76K mice and immunoprecipitated using Flag
antibody and Protein-G agarose beads. Immunoblot was performed using PY20
antibody following 10% SDS-polyacrylamide gel separation. (B) Protein was extracted
from the lungs of CCSP-rtTA/tetO-SHP2E76K mice and immunoprecipitated using Flag
antibody and Protein-G agarose beads. Immunoblot was performed using indicated
antibodies following 10% SDS-polyacrylamide gel separation. (C) Lungs were collected
from wild type and pre or post Dox induced CCSP-rtTA/tetO-SHP2E76K mice. Protein
extraction was followed by 10% SDS-polyacrylamide gel separation and immunoblot
with indicated antibodies. (WT - wild type, B - bitransgenic)
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Table 4. SHP2E76K bound proteins identified by mass spectrometry.
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Table 4 continued

Table contains top candidates with a minimum of 3 matching peptides. Protein
identification by mass spectrometry was performed by the Moffitt Cancer Center
Proteomics Core. Tryptic peptides from gel slides were analyzed with a nanoflow liquid
chromatograph coupled to an electrospray ion trap mass spectrometer for tandem mass
spectrometry peptide sequencing. Five tandem mass spectra were collected in a datadependent manner following each survey scan. Sequences were assigned using
Mascot (www.matrixscience.com) searches against mouse entries. (M.W. - Molecular
weight is an approximation, not exact value)

Previous work has shown that Gab1/SHP2 association is required for SHP2
activation and that GOF SHP2 mutants are non-functional if they lack intact SH2 binding
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domains [33, 34]. These studies indicate that acquisition of a GOF SHP2 mutation is not
sufficient to induce cellular transformation; recruitment of the PTP to the cell membrane
by docking proteins is a required step in this process. Since Gab1 is the main docking
protein of SHP2 and was identified in our mass spec analysis, we decided to focus our
attention on Gab1.
Dox induced CCSP-rtTA/tetO-SHP2E76K mice expressed elevated levels of
phosphorylated Gab1 compared to wild type controls or bitransgenic mice after Dox
withdrawal (Fig. 36C). To confirm these results, we expressed the SHP2E76K mutant in
TF-1 and H292 cells, and saw an increase in pGab1 as well as activation of the Src
family of kinases [60]. These results indicate that the SHP2E76K mutant can promote its
own activation by regulating the phosphorylation of its own docking protein.
To determine which protein tyrosine kinase is responsible for SHP2E76K mediated
Gab1 phosphorylation, we treated H292/SHP2E76K cells with Ruxolitinib, Dasatinib or
Erlotinib inhibitors which target Jak, SFKs, and EGFR respectively. Ruxolitinib had no
effect on pGab1 levels, while Dasatinib and Erlotinib significantly reduced Gab1
phosphorylation [60]. To determine whether Src activity is also required for induction of
Gab1 phosphorylation by a different GOF SHP2 mutant we treated H661 lung cancer
cells which express the SHP2N58S mutant with Dasatinib. As described earlier, Src
inhibition decreased pGab1 levels and caused a dissociation of the Gab1/SHP2
complex [60]. We further confirmed these results using a siRNA approach. Pan Src
knock-down using a Src SiRNA also reduced pGab1 levels in H661 cells [60]. To
identify specifically which SFK is responsible for Gab1 phosphorylation, we used siRNA
targeting Lyn and Lck. Only Lyn knock-down in H292/SHP2E76K cells decreased pGab1
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levels, indicating that Lyn is the mediator of SHP2E76K induced Gab1 phosphorylation
[60]. These results indicate that GOF SHP2 mutants potentially induce Gab1
phosphorylation through activation of the SFKs.
To confirm that this mechanism of Gab1 activation is specific to GOF SHP2 mutants,
we tested the erythroleukemia cell line Hel as a control. Cell transformation and
aberrant tyrosine phosphorylation events in this cell line are mediated by the GOF
Jak2V617F mutant. Ruxolitinib but not Dasatinib treatment inhibited Gab1 tyrosine
phosphorylation in Hel cells (Fig. 37). To verify the specificity of these two inhibitors, we
confirmed that Ruxolitinib treatment decreased Jak2 phosphorylation but not Src
phosphorylation, while Dasatinib reduced active Src but not pJak2 in these cells (Fig.
37).
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Figure 37. Ruxolitinib and Dasatinib treatment of Hel cells. Hel cells were grown to
confluence in complete medium then serum starved for 16 hours. Cells were treated
with indicated concentrations of Dasatinib or Ruxolitinib in complete medium for 24
hours followed by protein extraction. Immunoblot was performed with indicated
antibodies following 10% SDS-polyacrylamide gel separation.

3.5 Discussion
GOF SHP2 mutations are well known leukemic oncogenes but their contribution to
carcinogenesis is mostly undefined [177, 178]. SHP2E76K is a constitutively active GOF
SHP2 mutant found in human cancers, including NSCLC. To determine the role of
SHP2E76K in lung tumorigenesis, we generated a novel Dox inducible CCSP-rtTA/tetOSHP2E76K mouse model. SHP2E76K expression promoted Ras/MAPK and Src pathway
cell signaling by activating the Erk1/2 and Src kinases and increasing c-Myc levels.
After 6 months of Dox induction, the majority of CCSP-rtTA/tetO-SHP2E76K
bitransgenic mice displayed atypical adenomatous hyperplastic lesions and 31%
developed adenomas. At the 9 months time point, 87% of Dox-induced CCSPrtTA/tetO-SHP2E76K bitransgenic mice displayed adenomas and adenocarcinomas,
whereas only 15% of control mice of the same inbred strain developed lung tumors.
Moreover, the tumors found in control mice were notably smaller compared to those
found in bitransgenic CCSP-rtTA/tetO-SHP2E76K mice, indicating that SHP2E76K
expression might trigger earlier tumor onset, faster tumor growth, or both. The fact that
no control mice developed tumors at the 6 months time point further supports this
notion. These results demonstrate that the SHP2E76K mutant is a driver of
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carcinogenesis in lung epithelial cells and describe a novel role for SHP2 as a lung
cancer oncogene.
The majority of Dox induced CCSP-rtTA/tetO-SHP2E76K bitransgenic mice displayed
a tumor latency longer than 6 months. A potential explanation for this phenomenon is
that endogenous wild type SHP2 competes with the SHP2E76K mutant for the same
docking proteins thus reducing the transforming effect of SHP2E76K. This does not seem
to be the case in our mice though, since SHP2E76K expression positively regulated cell
signaling in the lungs of our bitransgenic mice. An alternative mechanism is that
SHP2E76K expression induces genomic instability leading to the acquisition of one or
more secondary mutations that promote the expansion of proliferative lesions. The
validity of this multigenic hypothesis is supported by the fact that CCSP-rtTA/tetO-Myc
mice display a long tumor latency of 300 days. The lung tumors observed in these mice
acquire a secondary Kras mutation. Moreover, tumor development is also accelerated in
mice by exposure to a chemical carcinogen or breeding onto a high Mcl1 background
[174]. Consistent with our previous finding that SHP2 upregulates c-Myc in lung
carcinoma cells in culture, we observed increased c-Myc levels in the lungs of Doxinduced CCSP-rtTA/tetO-SHP2E76K bitransgenic mice. Myc plays an important role in
cell proliferation and might significantly contribute to SHP2E76K mediated tumorigenesis
[153].
If the multigenic hypothesis of SHP2E76K mediated lung tumorigenesis is correct,
then tumor growth and survival should be independent of SHP2E76K expression. We
investigated this concept by taking advantage of the reversible feature of our Dox
inducible transgenic mouse model. We used an MRI approach to detect lung tumors in
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Dox induced bitransgenic mice. We then withdrew doxycycline for a month and
performed a second round of MRI. The MR images and follow-up histological evaluation
revealed that lung tumors not only stopped growing, but regressed in the absence of
SHP2E76K expression. These results indicate that tumor maintenance in Dox induced
CCSP-rtTA/tetO-SHP2E76K mice is dependent on sustained SHP2E76K expression and
that SHP2E76K is the main driver of lung carcinogenesis in this bitransgenic mouse
model.
Previous work has shown that augmentation of PTP activity is not sufficient to
induce cellular transformation. SHP2 must first be recruited to the cell membrane and
associate with docking proteins to function properly [33, 179]. This association is
mediated by phosphorylation of the SHP2 binding sites on the docking proteins. An
important question is since the GOF SHP2E76K mutant is clearly functional in the lungs
of our bitransgenic mice, how is phosphorylation of the docking protein maintained in
these animals? A potential answer is that GOF SHP2 mutants can positively regulate
the phosphorylation of their own docking protein. This notion is supported by previous
research in our lab showing that SHP2 knock-down in H292 cells impairs basal and
EGF stimulated tyrosine phosphorylation of the Gab1 SHP2 binding sites Y627 and
Y659 [153].
Since Gab1 is the main SHP2 docking protein and was identified as a top candidate
in our mass spectrometry experiment, we started by evaluating the tyrosine
phosphorylation of the SHP2 binding sites. We identified higher levels of pGab1 in the
lungs of our bitransgenic mice, TF-1/SHP2E76K cells, and H292/SHP2E76K cells. These
data indicate that SHP2E76K does indeed autoregulate the tyrosine phosphorylation of
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Gab1 and its binding to this docking protein. Additional experiments using PTK
inhibitors revealed that EGFR or SFKs inhibition by Erlotinib or Dasatinib reduces
pGab1 levels in H292/SHP2E76K and H661 cells. This effect can be replicated using
SFKs siRNAs in these cells. More specifically, Lyn knock-down had the strongest
impact on Gab1 phosphorylation in H661 cells. Since SHP2 knock-down has a negative
effect on SFKs activation and SHP2E76K expression increases pSrc levels in cell culture
models and the lungs of CCSP-rtTA/tetO-SHPE76K, our results suggests that the
SHP2E76K mutant promotes its own activation by activating the SFKs and triggering a
positive feed-forward loop system [153].

Figure 38. SHP2E76K mechanism of action in CCSP-rtTA/tetO-SHP2E76K mice. EGFR
phosphorylates Gab1 and recruits SHP2E76K which induces activation of the Lyn kinase.
Lyn then phosphorylates Gab1, initiating a positive feedback loop.
In conclusion, we have described a novel role for the GOF SHP2E76K mutation as an
oncogene in lung carcinoma by generating a Dox inducible transgenic mouse model
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that exhibits a disease phenotype similar to NSCLC patients. We also described a new
mechanism of GOF SHP2 mutant activation through a positive feedback loop involving
the docking protein Gab1 and the SFKs.
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Chapter 4: Concluding remarks

The protein tyrosine phosphatase SHP2 plays an important role in normal cellular
function. This protein is expressed ubiquitously and positively regulates multiple
signaling pathways, including the Ras/MAPK and Src cell signaling pathways resulting
in increased cell proliferation, survival, and motility [34, 36, 47, 180]. Because of its
extensive function, SHP2 also plays a prominent role in cancer [58]. GOF SHP2
mutations are known leukemic oncogenes, and SHP2 acts as a cancer essential gene
through over-expression or amplification in several types of malignancies [55, 59, 177].
Since the role of SHP2 in lung cancer is incompletely defined, the studies described in
this dissertation aim to elucidate the oncogenic potential of a GOF SHP2 mutant in vitro
and in vivo and to figure out whether SHP2 is a synthetic lethal gene in GOF EGFR
mutant dependent lung cancer.

4.1 Chapter 2 summary and conclusions
In the second chapter of this dissertation, we aimed to establish SHP2 as a synthetic
lethal gene in GOF EGFR mutant dependent lung cancer. To achieve this goal, we
performed in vitro experiments and generated a novel Dox inducible transgenic mouse
model expressing the dominant negative SHP2CSDA mutant under the control of the
CCSP promoter to direct expression to lung epithelial cells.
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Using two GOF EGFR mutant dependent lung cancer cell lines, we showed that
interfering with normal SHP2 function through shRNA knock-down, siRNA knock-down,
PTP catalytic domain inhibition, or expression of the dominant negative SHP2CSDA
mutant reduced cell proliferation and Ras/MAPK cell signaling pathway activity. These
results indicate that targeting SHP2 in vitro can have a significant effect on GOF EGFR
mediated cell signaling and proliferation.
Based on the previous results, we generated a Dox inducible transgenic mouse
model and bred bitransgenic CCSP-rtTA/tetO-EGFRL858R mice and tritransgenic CCSPrtTA/tetO-EGFRL858R/tetO-SHP2CSDA mice. Expression of the SHP2CSDA mutant in the
lungs of tritransgenic mice decreased EGFRL858R mediated Ras/MAPK and Src cell
signaling pathway activation, leading to delayed tumor onset and reduced tumor
burden.
To elucidate the mechanism of action of the SHP2CSDA mutant in the lungs of
tritransgenic mice, we performed a mass spectrometry analysis and identified Gab1 as
one of the main binding partners of SHP2CSDA. Further experiments in vitro revealed that
GOF EGFR mutants phosphorylated Gab1 on its SHP2 binding site, and that GOF
EGFR mutant inhibition caused a dissociation of the Gab1/SHP2 complex which might
be responsible for the decreased levels of pErk1/2, pSrc, and cell proliferation. These
results were further supported by showing that EGFRL858R expression in the lungs of
bitransgenic mice increased pGab1 levels and Gab1/SHP2 association, while SHP2CSDA
expression in tritransgenic mice countered these effects and fully disrupted Gab1/SHP2
complex formation.
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SHP2 is required to promote wild type EGFR mediated cell signaling [34, 150, 151].
In this project we demonstrated that SHP2 is also required to transduce GOF EGFR
mutant cell signaling and that targeting SHP2 has significant effects on GOF EGFR
mutant mediated lung tumorigenesis. Our work and others describes a novel role for
SHP2 as a synthetic lethal gene in GOF EGFR mutant dependent lung cancer [144]. In
a time where alternative options to EGFR tyrosine kinase inhibitors are urgently needed,
our results establish the potential of SHP2 as a novel therapeutic target for drug
development to treat GOF EGFR mutant dependent lung cancer patients.

4.2 Chapter 3 summary and conclusions
In the third chapter of this dissertation we determined whether the GOF SHP2E76K
mutant can induce tumor formation in the lungs of bitransgenic CCSP-rtTA/tetOSHP2E76K mice. We generated a novel doxycycline inducible transgenic mouse model
using the tet-on approach to induce transgene expression and used a recombinant
Clara cell secretory protein promoter to direct expression of the GOF SHP2E76K mutant
to lung epithelial cells.
SHP2E76K expression in the lungs of bitransgenic mice following one month of Dox
induction significantly increased levels of pErk1/2, pSrc, Myc and Mdm2. Myc is a
downstream target of SHP2 and an important driver of cell proliferation [153]. Elevated
Myc levels combined with the increased Ras/MAPK and Src cell signaling pathways
activation are most likely responsible for the appearance of atypical adenomatous
hyperplastic lesions and adenomas after 6 months of Dox induction. At the nine months
time point, a significant majority of bitransgenic CCSP-rtTA/tetO-SHP2E76K mice
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developed adenomas compared to wild type or monotransgenic controls. These results
establish the GOF SHP2E76K mutant as a novel driver oncogene of lung tumorigenesis
in our mouse model.
Since our bitransgenic mice displayed such a long latency to tumor development, we
suspected that the animals had acquired secondary mutations responsible for tumor
formation. Despite the presence of these additional mutations, we hypothesize that
SHP2E76K remained the main driver of tumorigenesis and that sustained transgene
expression was required for tumor maintenance. To test this hypothesis, we took
advantage of the reversible feature of our transgenic mouse model. We used MRI to
check for the presence of lung tumors in bitransgenic mice after nine months of Dox
induction then withdrew doxycycline for a month. A second round of MRI revealed that
the lung tumors had either regressed or completely disappeared indicating that while it
is highly likely that our bitransgenic mice acquired secondary mutations, the main driver
of tumorigenesis remained the GOF SHP2E76K mutant.
In an effort to determine the mechanism of SHP2E76K driven tumor formation in the
lungs of our bitransgenic CCSP-rtTA/tetO-SHP2E76K mice we performed a mass
spectrometry analysis to identify the binding partners of the SHP2E76K mutant. The
docking protein Gab1 was identified as one of the top candidates. Previous work has
shown that solely enhancing the catalytic activity of SHP2 through acquisition of a GOF
mutation is not sufficient to increase cell signaling, the GOF SHP2 mutant must be
recruited to the cell membrane to properly function [33, 34]. Gab1 is one of the main
docking proteins of SHP2 and association between the two proteins leads to SHP2
relocation to the cell membrane and activation [35]. Interestingly, we demonstrated that
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GOF SHP2 mutants can increase the phosphorylation level of Gab1 both in vitro and in
vivo, indicating that mutant SHP2 can auto-regulate the phosphorylation of its own
docking protein. Further work revealed that this mechanism is most likely mediated
through recruitment of the SFKs and is specific to GOF SHP2 mutants.
GOF SHP2 mutants are well known leukemic oncogenes, but their contribution to
carcinogenesis in solid tumors is mostly unknown. According to the COSMIC database,
GOF SHP2 mutations, including the SHP2E76K mutation used in our transgenic mouse
model, have been identified in about two percent of lung cancer cases, but their
potential contribution to tumorigenesis is unclear. Due to the high prevalence of lung
cancer, even two percent of cases accounts for a large number of patients. In this
project, we describe for the first time that a GOF SHP2 mutant can act as an oncogene
in lung epithelial cells, meaning that the GOF SHP2 mutations identified in lung cancer
patients could potentially be contributing or even driving carcinogenesis. Our results
establish SHP2 as a potential novel lung cancer oncogene and highlight a need to
further investigate the role of SHP2 in lung cancer to determine its potential as a
therapeutic target for drug development.
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